A kind of homoallyl compound and its preparation method and application
By controlling the rearrangement of cyclopropyl methylene cations using acid catalysis, the synthesis of homoallyl compounds addresses the limitations of existing technologies, the synthesis of homoallyl compounds achieves potent coronavirus 3CL protease inhibitors with IC50 values below 1 μM, enhancing their inhibitory activity.
Patent Information
- Application Number
- CN202210761099.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-06-29
AI Technical Summary
Existing methods for synthesizing cyclopropylmethylene cations result in complex rearrangement reactions, limiting their application range, and current SARS-CoV-2 3CL protease inhibitors exhibit suboptimal inhibitory effects with IC50 values above 15 μM.
A homoallyl compound is synthesized through controlled rearrangement of cyclopropyl methylene cations using acid catalysis, forming a tight ion pair with an anion to construct highly allyl products, which are then used to develop potent coronavirus 3CL protease inhibitors with IC50 values below 1 μM.
The synthesized homoallyl compounds demonstrate excellent inhibitory activity against coronavirus 3CL protease, offering broad application prospects with improved inhibitory efficacy.
Smart Images

Figure CN115073394B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of chemical synthesis, and specifically relates to a homoallyl compound and a preparation method and application thereof. Background Art
[0002] Cyclopropylmethylene cation (C4H7 + ) In 1951, Roberts et al. proposed an active cation with a symmetrical structure, believing that the non-classical carbon cation was stabilized by the delocalization effect in it, and the term "non-classical carbon cation" was first used and adopted by chemists. However, due to the complex rearrangement reaction path of the cyclopropyl methylene cation, and due to the influence of the surrounding substituents, it can open the ring to obtain a highly allylic product, open the ring to expand to obtain a cyclic or bridged ring product, and can also rearrange and expand to obtain a four-membered ring compound, so its application range is limited, as shown below:
[0003]
[0004] To solve this problem, based on the theoretical model, the Coulombic force and van der Waals force between the anion and the cyclopropyl methylene cation form a tight ion pair, and the rearrangement path of the cyclopropyl methylene carbon cation is controlled by the induction and steric hindrance effect of the anion to construct a highly allyl product. Through the experimental screening of reaction conditions such as acid (including chiral acid), reaction substrate, nucleophilic reagent and solvent, the effects of the spatial stereo configuration, electrostatic interaction and electronic effect of the acid on the reaction path and enantioselectivity are explored, the acid catalytic system is expanded and highly allyl compounds are efficiently constructed.
[0005] In addition, SARS-CoV-2 is a new type of β-CoV that has spread globally. 3CL protease, also known as 3CL pro or M pro , is a cysteine protease that can process the polyprotein precursors pp1a and pp1ab at no less than 11 conserved sites. It is responsible for releasing most of the non-structural functional proteins (NSPS) and participates in the replication and transcription process of the virus. pro The key role of 3CL in the viral life cycle and the lack of homologous proteins in human cells make it pro It has become a very attractive target for anti-SARS-CoV-2. pro Inhibitors targeting this target have been reported.
[0006] CN112574104A discloses a method for SARS-CoV-2 target M pro inhibitors of the acetamide class, but the IC 50The values are generally between 15-100 μM, showing no effect on the novel coronavirus M pro Particularly excellent inhibitory effect.
[0007] In vitro activity test data show that the homoallyl compounds provided by the present invention have good inhibitory activity against coronavirus 3CL protease, and their IC 50 The value can reach below 1μM, which has broad application prospects.
[0008] Therefore, it will be of great significance to synthesize compounds with high allyl groups using efficient, green, and convenient chemical synthesis methods and further conduct biological activity evaluation. Summary of the invention
[0009] In view of the shortcomings of the prior art, the present invention aims to provide a homoallyl compound and its preparation method and application. In vitro activity test data show that the homoallyl compound provided by the present invention has good inhibitory activity against coronavirus 3CL protease, and its IC 50 The value can reach below 1μM, which has broad application prospects.
[0010] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0011] In a first aspect, the present invention provides a homoallyl compound having a structure shown in the following formula I:
[0012]
[0013] wherein X is selected from sulfur or sulfonyl;
[0014] R1 and R2 are each independently selected from any one of hydrogen, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, and substituted or unsubstituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic group;
[0015] R3 and R4 are each independently selected from substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkenyl, substituted or unsubstituted C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkynyl, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) any one of C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) alkylamino, substituted or unsubstituted C3-C12 (for example, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkyl, substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, substituted or unsubstituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic group;
[0016] The R1, R2, R3, and R4 exist independently or are connected to form a ring Cy;
[0017] The ring Cy is selected from any one of a substituted or unsubstituted C3-C12 (for example, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkyl, a substituted or unsubstituted C3-C12 (for example, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkenyl, a substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, and a substituted or unsubstituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic group;
[0018] G is selected from hydrogen or any one of the following structures:
[0019]
[0020] DG is selected from hydrogen, cyano, nitro, hydroxyl, aldehyde, carboxyl, sulfonic acid, sulfonyl, ester, acyl, sulfone, silyl, carbonyl, halogen, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, substituted or unsubstituted C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkenyl, substituted or unsubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy, substituted or unsubstituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, substituted or unsubstituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic group, substituted or unsubstituted C3-C12 (for example, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkyl;
[0021] Indicates whether a chemical bond is in cis or trans configuration; Indicates the attachment site of a group.
[0022] In the present invention, the substituents of the substituted alkyl, substituted aryl, substituted heterocyclic, substituted alkenyl, substituted alkynyl, substituted alkoxy, substituted alkylamino, substituted cycloalkyl, and substituted cycloalkenyl are each independently selected from cyano, nitro, hydroxyl, aldehyde, carboxyl, sulfonic acid, sulfonyl, ester, acyl, sulfone, silyl, carbonyl, halogen, C1-C6 (for example, C1, C2, C3, C4, C C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkyl, C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkenyl, C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkoxyalkenyl, C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkynyl, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) such as C1, C2, C3, C4, C5, C6, etc.) alkylthio, C1-C6 (such as C1, C2, C3, C4, C5, C6, etc.) silyl, C1-C6 (such as C1, C2, C3, C4, C5, C6, etc.) alkylamino, C3-C12 (such as C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkane any one of a C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocycloalkyl, a C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl or a C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) arylalkyl.
[0023] In the present invention, R1 and R2 are each independently selected from any one of unsubstituted or Ra substituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, unsubstituted or Ra substituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic group; Ra is selected from any one of halogen, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkoxyalkenyl, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy or C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkylthio.
[0024] Preferably, said R1 and R2 are each independently selected from unsubstituted or R b Substituted phenyl; said R bAny one selected from halogen, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, C2-C6 (for example, C2, C3, C4, C5, C6, etc.) alkoxyalkenyl, C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy or C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkylthio.
[0025] In the present invention, R3 and R4 are each independently selected from unsubstituted or R c Substituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, wherein R c Selected from OTBS or OBn;
[0026] Or the R3 and R4 are connected to form a ring Cm;
[0027] The ring Cm is selected from unsubstituted or R d Substituted C3-C12 (e.g., C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkyl, unsubstituted or R d Substituted C3-C12 (e.g., C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) cycloalkenyl, unsubstituted or R d Substituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, unsubstituted or R d Any one of substituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic groups; said R d Any one selected from C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, carbonyl, acyl or sulfonyl.
[0028] Preferably, the R d Any one selected from C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, Boc (tert-butyloxycarbonyl), Piv (pivaloyl), Tos (p-toluenesulfonyl) or Nos (p-nitrobenzenesulfonyl).
[0029] In the present application, Nos and Ns are both p-nitrobenzenesulfonyl.
[0030] Preferably, DG is selected from hydrogen, halogen, unsubstituted or R e Substituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl, unsubstituted or R eSubstituted C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkoxy, unsubstituted or R e Substituted C6-C12 (for example, C6, C7, C8, C9, C10, C11, C12, etc.) aryl, unsubstituted or R e Any one of substituted C2-C12 (for example, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, etc.) heterocyclic groups; said R e Selected from C1-C6 (for example, C1, C2, C3, C4, C5, C6, etc.) alkyl or halogen.
[0031] In the present invention, the homoallyl compound is selected from any one of the structures shown in the following M1-M46:
[0032]
[0033]
[0034] In a second aspect, the present invention provides a tautomer, enantiomer, diastereomer or a pharmaceutically acceptable salt thereof of the homoallyl compound according to the first aspect.
[0035] Preferably, the pharmaceutically acceptable salt includes any one or a combination of at least two of hydrochloride, hydrobromide, phosphate, sulfate, methanesulfonate, p-toluenesulfonate, acetate, trifluoroacetate, salicylate, amino acid salt, citrate, maleate, tartrate, fumarate, citrate, lactate, sodium salt, potassium salt, calcium salt, magnesium salt, lithium salt, ammonium salt or a salt of an organic base that can provide a physiologically acceptable cation.
[0036] Preferably, the salt of the organic base capable of providing a physiologically acceptable cation includes any one of methylamine salt, dimethylamine salt, trimethylamine salt, piperidine salt, morpholine salt or tris(2-hydroxyethyl)amine salt, or a combination of at least two thereof.
[0037] In a third aspect, the present invention provides a method for preparing the homoallyl compound according to the first aspect, the preparation method comprising the following steps:
[0038] In the presence of an acid catalyst, the compound represented by formula II and the compound represented by formula III are mixed and reacted to obtain the compound represented by formula IV. The reaction formula is as follows:
[0039]
[0040] Alternatively, the preparation method further comprises the following steps:
[0041] The compound represented by formula IV is subjected to an oxidation reaction to obtain a compound represented by formula V. The reaction formula is as follows:
[0042]
[0043] It should be noted that, in the present invention, G in the structures shown in Formula III and Formula IV may be tautomers.
[0044] In the present invention, the acid catalyst includes an achiral acid or a chiral acid.
[0045] Preferably, the achiral acid comprises any one of CF3COOH, CF3SO3H or CF3SO2NHCF3SO2 or a combination of at least two thereof.
[0046] Preferably, the chiral acid is selected from any one or a combination of at least two of the following structures represented by C1a-C1d, C2a-C2b, C3a, C4a-C4f or C5; or the chiral acid is selected from any one or a combination of at least two of the enantiomers of the following structures represented by C1a-C1d, C2a-C2b, C3a, C4a-C4f or C5:
[0047]
[0048] Wherein, the Ar1-Ar 11 The structural formula is as follows:
[0049]
[0050] Preferably, the chiral acid has the structure shown below:
[0051]
[0052] In the present invention, the molar ratio of the compound represented by formula II to the compound represented by formula III is 1:(0.8-1.2), wherein "0.8-1.2" can be 0.8, 0.9, 1, 1.1, 1.2, etc.
[0053] Preferably, the molar ratio of the compound represented by formula II to the acid catalyst is 1:(0.05-0.3), wherein "0.05-0.3" can be 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, etc.
[0054] Preferably, the temperature of the mixed reaction of the compound represented by formula II and the compound represented by formula III is -94-30°C (for example, it can be -94°C, -84°C, -74°C, -64°C, -54°C, -44°C, -34°C, -24°C, -14°C, -4°C, 10°C, 20°C, 30°C, 34°C, etc.), and the time is 4-24h (for example, it can be 4h, 8h, 12h, 16h, 20h, 24h, etc.).
[0055] Preferably, the mixed reaction of the compound represented by Formula II and the compound represented by Formula III is carried out in a solvent, and the solvent includes toluene.
[0056] Preferably, the compound represented by formula IV undergoes an oxidation reaction in the presence of an oxidant, wherein the oxidant comprises (NH4)6Mo7O 24 (H2O)4.
[0057] Preferably, the oxidation reaction temperature of the compound represented by formula IV is 25-35°C (for example, it can be 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, etc.), and the time is 20-30h (for example, it can be 20h, 22h, 24h, 26h, 28h, 30h, etc.).
[0058] Preferably, the compound represented by formula IV undergoes oxidation reaction in the presence of a solvent, and the solvent comprises ethanol.
[0059] In a fourth aspect, the present invention provides a use of the homoallyl compound according to the first aspect or the tautomer, enantiomer, diastereomer or pharmaceutically acceptable salt thereof of the homoallyl compound according to the second aspect in the preparation of a coronavirus 3CL protease inhibitor.
[0060] Compared with the prior art, the present invention has the following beneficial effects:
[0061] The present invention provides a homoallyl compound and a preparation method and application thereof. The homoallyl skeleton compound provided by the present invention has a structure shown in Formula I; the preparation method provided by the present invention has simple synthesis steps, and the construction of the homoallyl compound can be achieved under the catalysis of an acid. The homoallyl skeleton compound provided by the present invention can be used to prepare a coronavirus 3CL protease inhibitor. In vitro activity test data show that the homoallyl compound provided by the present invention has good inhibitory activity against coronavirus 3CL protease, and its IC 50 The value can reach below 1μM, which has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] Figure 1 Compound M1 against SARS-CoV-1 3CL pro Schematic diagram of the inhibitory effect.
[0063] Figure 2 Compound M1 against SARS-CoV-2 3CL pro Schematic diagram of the inhibitory effect.
[0064] Figure 3 Compound M46 for SARS-CoV-1 3CL pro Schematic diagram of the inhibitory effect.
[0065] Figure 4 Compound M46 for SARS-CoV-2 3CL pro Schematic diagram of the inhibitory effect.
[0066] Figure 5 Compound M46 for SARS-CoV-2 3CL pro Time dependence curve of .
[0067] Figure 6 The graph is a graph of the natural logarithm of the residual enzyme activity versus the incubation time for different concentrations of compound M46.
[0068] Figure 7 It is a curve graph of kobs value and compound M46 concentration. DETAILED DESCRIPTION
[0069] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0070] Preparation Example 1
[0071] This preparation example provides compound 1a, and the preparation method of compound 1a comprises the following steps:
[0072]
[0073] Under nitrogen protection at -78°C, n-BuLi (2.5M hexane solution, 4 mL, 10 mmol) was added dropwise to a solution of bromoanisole (1.87 g, 10 mmol, 2.5 equiv) in THF (50 mL). After stirring for 30 minutes, a THF solution (5 mL) of exo-bicyclo[3.1.0]hexane-6-carboxylate (EB1) (620 mg, 4.0 mmol) was added via a syringe. Stir overnight at room temperature (16 h). Saturated NH4Cl solution (10 mL) and ether (200 mL) were added, and the organic phase was separated in a 1 L separatory funnel and washed with brine (200 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain a colorless oil; then purified by silica gel column chromatography (hexane / ether=5 / 1, Rf about 0.3) to obtain product 1a (1.1 g, 85% yield).
[0074] 1 H NMR (600MHz, CDCl3) δ7.30(d,J=8.8Hz,4H),6.83(d,J=8.8Hz,4H),3.80(s,6H),1.94(s,1H),1.81( dd,J=12.5,8.1Hz,2H),1.75–1.69(m,2H),1.65–1.60(m,1H),1.35–1.31(m,2H),1.28–1.22(m,2H). 13 C NMR (151MHz, CDCl3) δ158.4,140.0,128.1,113.1,77.4,55.3,29.6,27.5,21.9,21.8.HRMS(ESI):m / z: calcd.for 307.1698, found:307.1705.
[0075] Preparation Example 2
[0076] This preparation example provides compound 1b, and the preparation method of compound 1b is the same as that of preparation example 1.
[0077]
[0078] Colorless oil, yield 79%. 1H NMR (600MHz, CDCl3) δ7.28(d,J=8.8Hz,4H),6.84(d,J=8.8Hz,4H),6.09–6.02(m,2H),5.41(dd,J=17.3,1.7Hz,2H),5.28(dd,J=10.5,1.5Hz,2H),4.5 2(d,J=5.4Hz,4H),1.90(s,1H),1.80(dd,J=12.5,8.0Hz,2H),1.75–1.69( m,2H),1.63(dd,J=13.1,8.2Hz,1H),1.32–1.31(m,2H),1.27–1.23(m,2H). 13 C NMR (151MHz, CDCl3) δ157.5,140.1,133.4,128.1,117.7,113.9,77.4,68.9,29.6,27.5,21.9,21.8.HRMS(ESI):m / z: calcd.for 359.2011, found:359.2017.
[0079] Preparation Example 3
[0080] This preparation example provides compound 1c, and the preparation method of compound 1c is the same as that of preparation example 1.
[0081]
[0082] Colorless oil, yield 63%. 1 H NMR (600MHz, CDCl3) δ7.29(d,J=8.5Hz,4H),7.18(d,J=8.5Hz,4H),2.47(s,6H),1.90(s,1H),1.80( dd,J=12.4,8.2Hz,2H),1.75–1.69(m,2H),1.65–1.60(m,1H),1.34–1.31(m,2H),1.26–1.22(m,2H). 13 C NMR (151MHz, CDCl3) δ144.3, 137.1, 127.4, 126.1, 77.5, 29.3, 27.5, 21.9, 21.7, 15.9. HRMS (ESI): m / z: calcd.for 339.1241, found:339.1244.
[0083] Preparation Example 4
[0084] This preparation example provides compound 1d, and the preparation method of compound 1d is the same as that of preparation example 1.
[0085]
[0086] Colorless oil, yield 62%. 1 H NMR(600MHz, CDCl3)δ7.32(s,8H),1.95(s,1H),1.84–1.81(m,2H),1.76–1.71( m,2H),1.65-1.60(m,1H),1.38–1.37(m,2H),1.32(s,18H),1.31–1.21(m,2H). 13 C NMR (151MHz, CDCl3) δ149.6,144.6,126.5,124.7,77.6,34.5,31.5,29.5,27.5,21.9,21.8.HRMS(ESI):m / z: calcd.for 359.2739,found:359.2726.
[0087] Preparation Example 5
[0088] This preparation example provides compound 1e, and the preparation method of compound 1e is the same as that of preparation example 1.
[0089]
[0090] Colorless oil, yield 94%. 1 H NMR (600MHz, CDCl3) δ7.28(d,J=8.1Hz,4H),7.11(d,J=8.0Hz,4H),2.34(s,6H),1.92(s,1H),1.82( dd,J=12.7,8.3Hz,2H),1.75–1.69(m,2H),1.65–1.60(m,1H),1.35–1.33(m,2H),1.30–1.23(m,2H). 13 C NMR (151MHz, CDCl3) δ144.8,136.5,128.6,126.8,77.7,29.4,27.5,21.9,21.8,21.1.HRMS(ESI):m / z: calcdfor 275.1800, found: 275.1808.
[0091] Preparation Example 6
[0092] This preparation example provides compound 1f, and the preparation method of compound 1f is the same as that of preparation example 1.
[0093]
[0094] Colorless oil, yield 65%. H NMR (600 MHz, CDCl3) δ 7.29 (d, J = 8.8 Hz, 4H), 6.83 (d, J = 8.8 Hz, 4H), 3.79 (s, 6H), 1.90-1.86 (m, 3H), 1.68-1.62 (m, 2H), 1.28-1.21 (m, 5H), 0.94-0.92 (m, 2H). 13 C NMR (151MHz, CDCl3) δ158.4,139.9,128.1,113.2,77.7,55.3,34.4,23.2,21.6,13.4.HRMS(ESI):m / z: calcd.for 321.1855, found:321.1855.
[0095] Preparation Example 7
[0096] This preparation example provides compound 1g, and the preparation method of compound 1g is the same as that of Preparation Example 1.
[0097]
[0098] Colorless oil, yield 74%. 1 H NMR (600MHz, CDCl3) δ7.30(d,J=8.8Hz,4H),6.83(d,J=8.9Hz,4H),3.80(s,6H),2.20–2.16(m,2H),1.94(d,J=2 .2Hz,1H),1.81(d,J=13.7Hz,1H),1.73–1.70(m,2H),1.37–1.29(m,3H),1.22–1.09(m,3H),0.95–0.89(m,2H). 13 C NMR (151MHz, CDCl3) δ158.4,140.1,128.1,113.1,77.3,55.2,32.8,30.5,29.7,20.5.HRMS(ESI):m / z: calcd.for 335.2011, found:335.2013.
[0099] Preparation Example 8
[0100] This preparation example provides compound 1h. The preparation method of compound 1h is the same as that of preparation example 1.
[0101]
[0102] The colorless oil gradually turned into a white solid with a yield of 77% and a melting point of 86-88°C. 1 H NMR (600MHz, CDCl3) δ7.29(d,J=8.8Hz,4H),6.83(d,J=8.8Hz,4H),3.80(s,6H),2.00(dd,J=14.2,3.2Hz,2H),1.82(s,1 H), 1.66–1.61 (m, 2H), 1.56–1.52 (m, 2H), 1.38–1.31 (m, 4H), 1.11–1.05 (m, 2H), 0.97 (tJ=5.1Hz, 1H), 0.78–0.73 (m, 2H). 13 C NMR (151MHz, CDCl3) δ158.4,140.3,128.0,113.2,77.2,55.3,35.1,29.7,26.7,26.6,19.4.HRMS(ESI):m / z: calcd.for 349.2168, found:349.2176.
[0103] Preparation Example 9
[0104] This preparation example provides compound 1i, and the preparation method of compound 1i is the same as that of preparation example 1.
[0105]
[0106] White solid, yield 47%, melting point 76-78°C. 1 H NMR (600MHz, CDCl3) δ7.29(d,J=8.8Hz,4H),6.83(d,J=8.8Hz,4H),5.62(t,J=4.2Hz,2H),3.79(s,6H),2.32–2.28(m, 2H), 2.19–2.13 (m, 2H), 2.08–2.02 (m, 2H), 1.86 (s, 1H), 1.53–1.47 (m, 2H), 1.10 (t, J=5.5Hz, 1H), 0.99–0.94 (m, 2H). 13 C NMR (151MHz, CDCl3) δ158.4, 140.0, 130.3, 128.0, 113.2, 77.3, 55.3, 37.6, 29.3, 27.2, 20.3. HRMS (ESI): m / z: calcd.for 347.2011, found:347.2011.
[0107] Preparation Example 10
[0108] This preparation example provides compound 1j, and the preparation method of compound 1j is the same as that of preparation example 1.
[0109]
[0110] White solid, yield 74%. 1 H NMR(600MHz, CDCl3) δ7.29(d,J=8.9Hz,4H),6.83(d,J=8.8Hz,4H),3.91(d,J=8.3Hz,2H),3.79 (s,6H),3.72(d,J=8.2Hz,2H),1.97(d,J=3.1Hz,1H),1.72–1.71(m,2H),1.50(t,J=4.0Hz,1H). 13 C NMR (151MHz, CDCl3) δ158.6,139.7,127.9,113.4,76.4,69.8,55.3,30.2,21.9.HRMS(ESI): Calculate for 309.1490, found:309.1491.
[0111] Preparation Example 11
[0112] This preparation example provides compound 1k. The preparation method of compound 1k is the same as that of Preparation Example 1.
[0113]
[0114] Colorless oil, yield 68%. 1 H NMR(600MHz, CDCl3) δ7.26(d,J=7.8Hz,4H),7.11(d,J=7.8Hz,4H),3.92(d,J=8.3Hz,2H), 3.72(d,J=8.2Hz,2H),2.33(s,6H),1.92(s,1H),1.74–1.73(m,2H),1.54(t,J=4.0Hz,1H). 13 C NMR (151MHz, CDCl3) δ144.4,136.8,128.8,126.6,76.7,69.8,29.9,21.8,21.1.HRMS(ESI): Calculate for 277.1592, found:277.1600.
[0115] Preparation Example 12
[0116] This preparation example provides compound 11, and the preparation method of compound 11 is the same as that of Preparation Example 1.
[0117]
[0118] White solid, yield 44%. 1 H NMR(600MHz, CDCl3) δ6.87(dd,J=8.1,1.8Hz,2H),6.84(d,J=1.8Hz,2H),6.74(d,J=8.1Hz,2H),5.93(s,4H) ,3.90(d,J=8.3Hz,2H),3.71(dd,J=8.4,1.8Hz,2H),1.98(s,1H),1.73–1.72(m,2H),1.43(t,J=4.0Hz,1H). 13 C NMR (151MHz, CDCl3) δ147.5,146.7,141.4,119.8,107.7,107.6,101.1,76.7,69.8,30.2,21.9.HRMS(ESI): Calculate for 337.1076, found:337.1086.
[0119] Preparation Example 13
[0120] This preparation example provides compound 1m, and the preparation method of compound 1m is the same as that of preparation example 1.
[0121]
[0122] Colorless oil, yield 28%. 1 H NMR (600MHz, CDCl3) δ7.28 (d, J = 8.7Hz, 4H), 6.83 (d, J = 8.8Hz, 4H), 4.12 (d, J = 13. 1Hz, 2H), 3.81–3.79 (m, 8H), 1.91 (t, J=5.5Hz, 1H), 1.36 (s, 3H) 1.29–1.25 (m, 6H). 13 C NMR (151MHz, CDCl3) δ158.6, 139.8, 127.9, 113.4, 102.6, 76.4, 61.4, 55.3, 32.6, 25.3, 23.8, 20.8.HRMS (ESI): Calculate for 367.1909, found:367.1907.
[0123] Preparation Example 14
[0124] This preparation example provides compound 1n, and the preparation method of compound 1n is the same as that of preparation example 1.
[0125]
[0126] Colorless oil, yield 87%. 1 H NMR (600MHz, CDCl3) δ7.24(d,J=8.7Hz,4H),6.83(d,J=8.8Hz,4H),4.32(dd,J=12.3,3.6Hz,2H),3.79(s, 6H), 3.75 (dd, J=12.4, 8.8Hz, 2H), 1.89 (s, 1H), 1.70–1.64 (m, 3H), 1.05–1.02 (m, 13H), 0.98–0.94 (m, 1H). 13 C NMR (151MHz, CDCl3) δ158.7, 139.6, 139.6, 127.7, 113.4, 75.7, 64.7, 55.3, 36.8, 22.8, 17.2, 17.0, 12.3, 12.1.HRMS (ESI): Calculate for 439.2305, found:439.2316.
[0127] Preparation Example 15
[0128] This preparation example provides compound 1o, and the preparation method of compound 1o is the same as that of preparation example 1.
[0129]
[0130] Colorless oil, yield 90%. 1 H NMR (600MHz, CDCl3) δ7.39 (d, J=8.8Hz, 4H), 6.81 (d, J=8.8Hz, 4H), 3.81–3.78 (m, 8H), 3.63 (dd, J=10. 9, 6.9Hz, 2H), 2.26 (s, 1H), 1.55 (t, J = 5.5Hz, 1H), 1.19 (q, J = 4.8Hz, 2H), 0.91 (s, 18H), 0.05 (s, 12H). 13C NMR (151MHz, CDCl3) δ158.4,139.4,128.3,113.1,76.7,62.5,55.3,34.2,26.1,22.2,18.4,-5.2,-5.3.HRMS (ESI): Calculate for 555.3326, found:555.3344.
[0131] Preparation Example 16
[0132] This preparation example provides compound 1p. The preparation method of compound 1p is the same as that of preparation example 1.
[0133]
[0134] Colorless oil, yield 88%. 1 H NMR(600MHz, CDCl3)δ7.39–7.26(m,14H),6.78(d,J=8.8Hz,4H),4.45(s,4H),3.77(s,6H),3 .64–3.61(m,2H),3.53–3.50(m,2H),2.11(s,1H),1.55(t,J=5.4Hz,1H),1.44–1.42(m,2H). 13 C NMR (151MHz, CDCl3) δ158.5, 139.4, 138.6, 128.4, 128.2, 127.7, 127.6, 113.3, 76.4, 72.7, 69.5, 55.3, 34.0, 19.4.HRMS (ESI): Calculate for 507.2535, found:507.2551.
[0135] Preparation Example 17
[0136] This preparation example provides compound 1q. The preparation method of compound 1q is the same as that of preparation example 1.
[0137]
[0138] Colorless oil, yield 75%. 1H NMR (600MHz, CDCl3) δ7.29(d,J=8.8Hz,4H),6.83(dd,J=7.6,4.5Hz,4H),3.79(s,6H),3.66(dd,J=10.8,5.9Hz,1H ),3.52(d,J=10.8Hz,1H),3.42–3.35(m,2H),1.99(s,1H),1.67–1.61(m,2H),1.43(s,9H),1.32(t,J=3.1Hz,1H). 13 CNMR (151MHz, CDCl3) δ158.7,158.6,155.1,139.8,139.2,128.0,127.8,113.4 ,79.4,76.5,76.5,55.3,48.6,48.3,33.1,33.1,28.6,20.8,20.4.HRMS(ESI): Calculate for 448.2100, found:448.2094.
[0139] Preparation Example 18
[0140] This preparation example provides compound 1r, and the preparation method of compound 1r is the same as that of preparation example 1.
[0141]
[0142] Colorless oil, yield 63%. 1 H NMR (600MHz, CDCl3) δ7.27 (d, J=9.1Hz, 4H), 6.83 (d, J=8.8Hz, 4H), 3.97 (s, 2H), 3.7 9(s,6H),3.52(s,2H),2.05(s,1H),1.70(s,2H),1.25(t,J=3.8Hz,1H),1.21(s,9H). 13 C NMR (151MHz, CDCl3) δ177.4,158.7,127.8,113.4,76.5,55.3,50.0,39.1,32.2,27.6.HRMS(ESI): Calculate for 432.2151, found:432.2162.
[0143] Preparation Example 19
[0144] This preparation example provides compound 1s, and the preparation method of compound 1s is the same as that of preparation example 1.
[0145]
[0146] Colorless oil, yield 95%. 1 H NMR (600MHz, CDCl3) δ7.66(d,J=8.2Hz,2H),7.30(d,J=7.5Hz,2H),7.19(d,J=8.8Hz,4H),6.80(d,J=8.8Hz,4H),3.78 (s,6H),3.59(d,J=9.5Hz,2H),3.08–3.06(m,2H),2.40(s,3H),1.89(s,1H),1.59–1.58(m,2H),1.46(t,J=3.8Hz,1H). 13 C NMR (151MHz, CDCl3) δ158.7,143.6,139.3,133.3,129.7,127.7,127.6,113.4,76.0,55.3,50.1,30.8,21.6,20.5.HRMS(ESI): Calculate for 462.1739, found:462.1755.
[0147] Preparation Example 20
[0148] This preparation example provides compound 1t, and the preparation method of compound 1t is the same as that of preparation example 1.
[0149]
[0150] Yellow oil, yield 98%. 1 H NMR (600MHz, CDCl3) δ8.36(d,J=8.8Hz,2H),7.96(d,J=8.8Hz,2H),7.19(d,J=8.7Hz,4H),6.82(d,J=8.8Hz,4H ),3.79(s,6H),3.66(d,J=9.4Hz,2H),3.13(d,J=9.6Hz,2H),1.84(s,1H),1.68(s,2H),1.44(t,J=3.8Hz,1H). 13 CNMR(151MHz, CDCl3)δ158.8,150.2,142.3,139.2,128.6,127.6,124.4,113.5,75.9,55.3,50.3,31.1,20.6.HRMS(ESI): Calculate for 493.1433, found:493.1423.
[0151] Preparation Example 21
[0152] This preparation example provides compound 1u.
[0153]
[0154] Compound a: 1 H NMR (600MHz, CDCl3) δ7.32–7.24(m,9H),6.84–6.82(m,4H),3.80(s,6H),3.62(s,2H) ,3.06(d,J=8.8Hz,2H),2.42(d,J=9.0Hz,2H),2.02–1.95(m,2H),1.49–1.48(m,2H). 13 C NMR (151MHz, CDCl3) δ158.5,139.9,139.9,128.7,128.2,128.1,126.9,113.2,77.0,59.3,55.3,54.8,29.8,20.7.HRMS(ESI): Calculate for 416.2226,found:416.2222.
[0155] Compound b: Add compound a, methanol and 10% Pd / C into an autoclave, fill with 10 atm of hydrogen, and react at room temperature overnight. White solid b is obtained with a yield of 96%. 1 H NMR(600MHz, CDCl3) δ7.28(d,J=8.8Hz,4H),6.83(d,J=8.8Hz,4H),3.79(s,6H),3.02 (d,J=11.3Hz,2H),2.90(d,J=11.2Hz,2H),1.52–1.51(m,2H),1.28(t,J=3.9Hz,1H). 13 C NMR (151MHz, CDCl3) δ158.5,139.8,128.0,113.2,76.6,55.3,48.7,29.2,22.0.HRMS(ESI): calcd.for 326.1756, found:326.1752.
[0156] Compound 1u: Compound b (325.4 mg, 1.0 mmol) and compound c (569.0 mg, 2.0 mmol) were added to the reaction flask, and then solvent DCM (10 mL), DIPEA (646.2 mg, 5.0 mmol), HATU (758.5 mg, 2.0 mmol) were added, and the reaction was allowed to proceed overnight. Water was added, and EA was extracted twice, the organic phases were combined, concentrated under reduced pressure, and then purified by silica gel column chromatography (PE / EA=2 / 1, Rf about 0.2) to obtain product 1u (331 mg, 56% yield).
[0157] Colorless oil, yield 56%. 1 H NMR (600MHz, CDCl3) δ7.27 (dd, J=8.8, 3.3Hz, 4H), 6.84 (dd, J=8.9, 7.4Hz, 4H) ,3.93(d,J=12.0Hz,1H),3.80(s,3H),3.79(s,3H),3.59–3.55(m,2H),3.44(dd ,J=12.0,4.7Hz,1H),2.22–2.17(m,2H),1.91(s,1H),1.78–1.75(m,J=1H),1. 72–1.69(m,1H),1.59–1.57(m,1H),1.29–1.24(m,30H),0.88(t,J=7.0Hz,3H). 13 C NMR (151MHz, CDCl3) δ172.8,158.8,158.7,139.8,139.0,128.1,127.7,113.5,113.5,76.4,55.4,55.3,49.3 ,48.1,35.1,33.4,32.0,29.8,29.7,29.7,29.6,29.6,29.6,29.4,25.0,22.8,20.8,20.2,14.2.HRMS(ESI): Calculate for 592.4366,found:592.4354.
[0158] Preparation Example 22
[0159] This preparation example provides compound 1v, and the preparation method of compound 1v is the same as that of preparation example 1u.
[0160]
[0161] Colorless oil, yield 92%. HRMS (ESI): Calculate for 674.3324, found:674.3318.
[0162] Preparation Example 23
[0163] This preparation example provides compound 1h'. The preparation method of compound 1h' is the same as that of preparation example 1.
[0164]
[0165] White solid, yield 82%. 1 H NMR (600MHz, Acetone) δ7.35(d,J=8.8Hz,4H),6.84(d,J=8.8Hz,4H),3.77(s,6H),2.07–2.01(m,3H) ,1.68–1.57(m,6H),1.49(t,J=9.2Hz,1H),1.40–1.35(m,2H),1.32–1.27(m,2H),0.92–0.89(m,2H). 13 C NMR (151MHz, Acetone) δ160.0, 144.5, 129.7, 114.5, 79.4, 56.3, 32.1, 31.7, 28.2, 23.6, 22.3.HRMS (ESI): calcdfor 349.2168, found:349.2160.
[0166] Preparation Example 24
[0167] This preparation example provides compound 1i'. The preparation method of compound 1i' is the same as that of preparation example 1.
[0168]
[0169] White solid, yield 76%. 1 H NMR (600MHz, CDCl3) δ7.36(d,J=8.7Hz,4H),6.85(d,J=8.9Hz,4H),5.62(t,J=4.3Hz,2H),3.81(s,6H),2.50–2.46(m, 2H),2.37–2.33(m,2H),2.05–2.00(m,2H),1.82–1.79(m,2H),1.69(s,1H),1.49(t,J=9.2Hz,1H),1.16–1.12(m,2H). 13 C NMR (151MHz, CDCl3) δ158.4,142.2,129.7,127.8,113.3,78.8,55.3,29.4,28.2,23.7,20.0.HRMS(ESI): Calculate for 347.2011, found:347.2020.
[0170] Preparation Example 25
[0171] This preparation example provides a chiral acid catalyst C4e, and the preparation method of the chiral acid catalyst C4e comprises the following steps:
[0172]
[0173] In a Schlenk flask under N2 protection, compound C1 (0.75 g, 1.24 mmol, 1.00 equiv.) was dissolved in DCM (10 mL), and then compound C2 (0.71 g, 2.48 mmol, 2.00 equiv.) and DMAP (0.76 g, 6.20 mmol, 5.00 equiv.) were added to the reaction system. After stirring at -40 °C for 1 hour, the reaction mixture was washed with water. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. Purified by silica gel column chromatography (eluent petroleum ether: ethyl acetate = 5:1), the obtained product was dissolved in THF, and then 2 mL of 2M KOH (aqueous solution) was added. The reaction mixture was extracted twice with ethyl acetate. The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The product was purified by silica gel column chromatography (eluent DCM: methanol = 10: 1), and then dissolved in acetonitrile, acidified with 6M HCl (aqueous solution), and dried in vacuo to give a white solid (0.71 g, 72%).
[0174] 1 H NMR (600MHz, CDCl3) δ8.43(s,1H),8.36(s,1H),7.96–7.93(m,3H),7.81–7.74(m,3H),7.61(dd,J=17.3,8.4Hz,2H),7.42– 7.38(m,10H),7.23–7.20(m,2H),4.28(s,2H),3.39–3.33(m,2H),3.19–3.11(m,2H),2.63–2.57(m,2H),2.48–2.40(m,2H). 13C NMR (151MHz, CDCl3) δ147.4,145.9,143.4,143.3,142.3,139.7,133.9,133 .7,131.6,131.3,131.2,131.1,130.8,130.3,129.6,129.5,129.3,128.8, 128.6,128.6,128.2,128.0,127.8,127.5,126.7,126.0,125.7,125.6,125.4,125.4,124.8,124.6,124.4,123.5,119.0,60.6,39.4,38.7,30.5,30.4. 19 F NMR (565MHz,CDCl3)δ-77.3. 31 P NMR (243MHz,CDCl3)δ-16.8.
[0175] Example 1
[0176] This embodiment provides a compound M1, and the preparation method of the compound M1 comprises the following steps:
[0177]
[0178] 0.01 mmol of compound 1a, 0.01 mmol of compound 2a, 0.001 mmol of catalyst C4e, 20 mg Molecular sieves and 1 mL of toluene were added to the reactor. After the addition was completed, the reaction was stirred at -94°C under nitrogen protection for 6 hours. The reaction was terminated and separated by column chromatography to obtain a colorless oily liquid, namely compound M1 (yield: 91%).
[0179] The enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA = 90 / 10, flow rate = 1.0 mL / min, λ = 254 nm.t R =6.49min(minor),t R =7.20min(major),er=4.0:96.0. 1H NMR (600MHz, CDCl3) δ7.89(d,J=8.1Hz,1H),7.73(d,J=7.8Hz,1H),7.42(t,J=8.3Hz,1H),7. 29(t,J=8.2Hz,1H),7.11(d,J=8.6Hz,2H),7.05(d,J=8.8Hz,2H),6.88(d,J=8.6Hz,2H),6.7 0(d,J=8.8Hz,2H),5.89(d,J=10.0Hz,1H),4.02–3.98(m,1H),3.82(s,3H),3.75(s,3H),2.7 4–2.68(m,1H),2.54–2.47(m,1H),2.00–1.95(m,1H),1.86–1.74(m,3H),1.67–1.60(m,1H). 13 C NMR (151MHz, CDCl3) δ167.4,158.8,158.6,153.4,142.1,135.4,135.3,132.5,131.0, 129.1, 128.4, 126.0, 124.2, 121.5, 120.9, 113.6, 113.4, 55.3, 55.2, 53.5, 47.0, 34.1, 33.3, 23.6. HRMS (ESI) m / z: calcd.for 474.1561, found:474.1567. (c 0.16, CHCl3) for 92% ee.
[0180] Example 2
[0181] This example provides a compound M2, and the preparation method of the compound M2 is the same as that of Example 1:
[0182]
[0183] Colorless oil, yield 86%. Enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=1.0 mL / min, λ=254 nm.t R =5.63min(minor), t R =6.08min (major), er=10.5:89.5. 1H NMR (600MHz, CDCl3) δ7.88 (d, J=8.1Hz, 1H), 7.73 (d, J=7.9Hz, 1H), 7.42 (t, J=7.7Hz, 1H), 7.28 (t, J=7.6Hz, 1H), 7.09 (d, J=6.7 Hz, 2H), 7.04 (d, J=7.0Hz, 2H), 6.88 (d, J=6.8Hz, 2H), 6.71 (d, J=7.0Hz, 2H), 6.12-5.99 (m, 2H), 5.89 (d, J=11.8Hz, 1H), 5.45 (d, J=17.2Hz, 1H), 5.38 (d, J=17.3Hz, 1H), 5.31 (d, J=10.3Hz, 1H), 5.26 (d, J=10.2Hz, 1H), 4.54 (d, J=5.4Hz, 2H), 4.48 (d, J=5.4Hz , 2H), 3.98 (q, J=7.3Hz, 1H), 2.70 (p, J=8.1Hz, 1H), 2.53-2.49 (m, 1H), 1.98-1.95 (m, 1H), 1.84-1.76 (m, 3H), 1.66-1.59 (m, 1H). 13 C NMR (151MHz, CDCl3) δ167.4, 157.9, 157.7, 153.5, 142.1, 135.4, 135.4, 133.5, 133.4, 132.6, 131.0, 129.2, 128.4, 126.0, 124.2, 121.6, 120.9, 117.8, 117.7, 114.4, 114.2, 68.9, 68.8, 53.5, 47.0, 34.1, 33.3, 23.7.HRMS (ESI) m / z: calcd.for 526.1874, found: 526.1872. (c 0.16, CHCl3) for 79% ee.
[0184] Example 3
[0185] This embodiment provides a compound M3. The preparation method of the compound M3 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0186]
[0187] Colorless oil, yield 86%. Enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=1.0 mL / min, λ=254 nm.t R =6.56min(minor), t R =7.35min (major), er=2.5:97.5. 1 H NMR (600MHz, CDCl3) δ7.88 (d, J=9.2Hz, 1H), 7.73 (d, J=7.9Hz, 1H), 7.42 (t, J=8.3Hz , 1H), 7.30-7.28 (m, 1H), 7.21 (d, J=8.2Hz, 2H), 7.09 (d, J=8.2Hz, 2H), 7.04-7.00 (m, 4H), 5.98 (d, J=10.1Hz, 1H), 4.03-3.99 (m, 1H), 2.72-2.66 (m, 1H), 2.52-2.47 (m, 1H) , 2.50(s, 3H), 2.42(s, 3H), 1.99-1.93(m, 1H), 1.86-1.74(m, 3H), 1.65-1.60(m, 1H). 13 C NMR (151MHz, CDCl3) δ167.1, 153.4, 141.9, 139.1, 137.3, 137.2, 136.5, 135.4, 130.7, 130.4, 127.6, 126.3, 126.2, 126.1, 124.2, 121.6, 121.0, 53.3, 47.2, 34.0, 33.3, 23.6, 15.9, 15.7. HRMS (ESI) m / z: calcd.for 506.1105, found: 506.1107. (c0.14, CHCl3) for 95% ee.
[0188] Example 4
[0189] This embodiment provides a compound M4. The preparation method of the compound M4 is different from that of the embodiment 1 only in that the reaction temperature is -20°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0190]
[0191] Colorless oil, yield 95%. The enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=95 / 5, flow rate=1.0 mL / min, λ=254 nm.t R =4.36min(major), t R =5.08min (minor), er=60.0:40.0. 1 H NMR (600MHz, CDCl3) δ7.89 (d, J=8.2Hz, 1H), 7.74 (d, J=7.9Hz, 1H), 7.42 (t, J=7.7Hz, 1H), 7.34 (d, J=6.3Hz, 2H), 7.30-7.28 (m, 1H), 7.21 (d, J=7.5Hz, 2H), 7.12 (d, J=8.2Hz, 2H), 7.09 (d, J=8. 5Hz, 2H), 6.00 (d, J=10.1Hz, 1H), 4.01 (q, J=8.9, 8.1Hz, 1H), 2.73 (q, J=9.7Hz, 1H), 2.56-2.52 (m, 1H), 2.01-1.97 (m, 1H), 1.85-1.77 (m, 3H), 1.66-1.62 (m, 1H), 1.35 (s, 9H), 1.28 (s, 9H).13C NMR (151MHz, CDCl3) δ167.4, 153.5, 149.9, 149.7, 142.7, 139.5, 136.8, 135.5, 130.1, 129.5, 126.8, 126.0, 12 5.0, 125.0, 124.9, 124.1, 121.6, 120.9, 53.5, 46.8, 34.6, 34.5, 34.2, 33.4, 31.5, 31.4, 23.7.HRMS (ESI) m / z: calcd.for 526.2602, found: 526.2591. (c 0.1, CHCl3) for 20% ee.
[0192] Example 5
[0193] This embodiment provides a compound M5. The preparation method of the compound M5 is different from that of embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of embodiment 1.
[0194]
[0195] Colorless oil, yield 91%. Enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=95 / 5, flow rate=0.8 mL / min, λ=254 nm.t R =5.21min(minor), t R =5.64min (major), er=33.5:66.5. 1 H NMR (600MHz, CDCl3) δ7.90 (d, J=8.2Hz, 1H), 7.74 (d, J=8.0Hz, 1H), 7.43 (t, J=7.8Hz, 1H), 7.3 0 (t, J=7.7Hz, 1H), 7.16 (d, J=7.5Hz, 2H), 7.09 (d, J=7.7Hz, 2H), 7.04 (d, J=7.9Hz, 2H), 6.99 ( d, J=7.8Hz, 2H), 5.98 (d, J=9.7Hz, 1H), 4.02 (q, J=8.0Hz, 1H), 2.72 (p, J=9.2Hz, 1H), 2.55-2. 51 (m, 1H), 2.38 (s, 3H), 2.30 (s, 3H), 2.00-1.97 (m, 1H), 1.86-1.75 (m, 3H), 1.68-1.63 (m, 1H). 13 C NMR (151MHz, CDCl3) δ167.4, 153.5, 142.9, 139.6, 137.1, 136.7, 136.6, 135.4, 130.0, 129.8, 128.9, 128.7, 127.1, 126.0, 124.1, 121.5, 120.9, 53.4, 46.9, 34.2, 33.3, 23.7, 21.3, 21.1. HRMS (ESI) m / z: calcd.for 442.1663, found: 442.1655. (c0.10, CHCl3) for 33% ee.
[0196] Example 6
[0197] This example provides a compound M6, and the preparation method of the compound M6 is the same as that of Example 1:
[0198]
[0199] Colorless oil, yield 88%. Enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=1.0 mL / min, λ=254 nm.t R =5.60min(minor), t R =7.90min (major), er=8.5:91.5. 1 H NMR (600MHz, CDCl3) δ7.90 (d, J=8.1Hz, 1H), 7.71 (d, J=7.9Hz, 1H), 7.43 (t, J=8.3Hz, 1H), 7. 29 (t, J=8.2Hz, 1H), 7.11 (d, J=8.6Hz, 2H), 6.94 (d, J=8.8Hz, 2H), 6.90 (d, J=8.6Hz, 2H), 6.6 1 (d, J=8.8Hz, 2H), 5.86 (d, J=10.2Hz, 1H), 3.89-3.86 (m, 1H), 3.84 (s, 3H), 3.72 (s, 3H), 2.4 2-2.36(m, 2H), 1.90-1.86(m, 1H), 1.78-1.73(m, 2H), 1.51-1.43(m, 3H), 1.28-1.22(m, 1H). 13 C NMR (151MHz, CDCl3) δ167.1, 158.7, 158.5, 153.5, 141.0, 135.5, 135.3, 132.7, 130.8, 130.6, 128.3, 12 6.0, 124.1, 121.5, 121.0, 113.7, 113.3, 55.3, 55.2, 53.3, 44.0, 34.2, 33.6, 26.4, 25.1.HRMS (ESI) m / z: calcd.for 488.1718, found: 488.1722. (c 0.2, CHCl3) for 83% ee.
[0200] Example 7
[0201] This example provides a compound M7, and the preparation method of the compound M7 is the same as that of Example 1:
[0202]
[0203] Colorless oil, yield 87%. Enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=1.0 mL / min, λ=254 nm.t R =5.42min(minor), t R =7.26min (major), er=10.0:90.0. 1 H NMR (600MHz, CDCl3) δ7.88 (d, J=9.1Hz, 1H), 7.73 (d, J=7.8Hz, 1H), 7.42 (t, J=8.3Hz, 1H), 7. 28(t, J=8.2Hz, 1H), 7.10 (dd, J=17.3, 8.8Hz, 4H), 6.90 (d, J=8.6Hz, 2H), 6.72 (d, J=8.7Hz, 2H ), 6.03 (d, J=10.4Hz, 1H), 4.05-4.02 (m, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 2.58-2.53 (m, 1H), 2. 25-2.20(m, 1H), 2.01-1.95(m, 1H), 1.88-1.79(m, 1H), 1.80-1.57(m, 6H), 1.51-1.44(m, 1H). 13 C NMR (151MHz, CDCl3) δ167.6, 158.8, 158.5, 153.5, 140.0, 135.4, 135.4, 132.6, 131.7, 130.9, 128.4, 125.9 , 124.1, 121.5, 120.9, 113.6, 113.4, 55.6, 55.3, 55.2, 44.7, 34.7, 34.1, 28.6, 25.8, 25.8.HRMS (ESI) m / z: calcd.for 502.1874, found: 502.1873. (c 0.12, CHCl3) for 80% ee.
[0204] Example 8
[0205] This embodiment provides a compound M8. The preparation method of the compound M8 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0206]
[0207] Colorless oil, yield 85%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=85 / 15, flow rate=1.0 mL / min, λ=254 nm.t R =5.75min(major), t R =7.67min (minor), er=86.0:14.0. 1 H NMR (600MHz, CDCl3) δ7.89 (d, J=8.1Hz, 1H), 7.73 (d, J=8.0Hz, 1H), 7.42 (t, J=8.3Hz, 1H), 7.28 (t, J=8 .2Hz, 1H), 7.14 (d, J=8.5Hz, 2H), 7.06 (d, J=8.7Hz, 2H), 6.93 (d, J=8.6Hz, 2H), 6.69 (d, J=8.8Hz, 2H), 6.03(d, J=10.3Hz, 1H), 4.21-4.18(m, 1H), 3.85(s, 3H), 3.74(s, 3H), 2.68-2.63(m, 1H), 2.24-2.20(m , 1H), 2.09-2.03(m, 1H), 1.93-1.89(m, 1H), 1.81-1.60(m, 6H), 1.55-1.44(m, 2H), 1.38-1.33(m, 1H). 13 CNMR (151MHz, CDCl3) δ167.7, 158.7, 158.5, 153.5, 140.1, 135.4, 135.3, 132.8, 131.9, 130.9, 128.3, 125.9, 1 24.1, 121.5, 120.9, 113.7, 113.4, 55.3, 55.3, 55.2, 42.0, 32.0, 32.0, 26.4, 26.1, 26.1, 26.0.HRMS (ESI) m / z: calcd.for 516.2031, found: 516.2034. (c 0.18, CHCl3) for 72% ee.
[0208] Example 9
[0209] This embodiment provides a compound M9. The preparation method of the compound M9 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0210]
[0211] Colorless oil, yield 75%. The enantiomeric ratio was determined by HPLC analysis using OD (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=1.0 mL / min, λ=254 nm. From exo-t R =6.04min(minor), t R =6.45min (major), er=8.0:92.0. 1 H NMR (600MHz, CDCl3) δ7.88 (d, J=8.1Hz, 1H), 7.74 (d, J=7.9Hz, 1H), 7.41 (t, J=7.7Hz, 1H), 7.29 (t, J=7.5Hz, 1H), 7.15 (dd, J=8.7, 3.5Hz, 4H), 6.93 (d, J=8.5Hz, 2H), 6.77 (d, J=8.8Hz, 2H), 6.07 (d, J =10.7Hz, 1H), 5.71-5.59(m, 2H), 4.31-4.27(m, 1H), 3.86(s, 3H), 3.77(s, 3H), 2.88-2.83(m, 1H), 2.46 (dq, J=15.0, 7.7Hz, 1H), 2.27-2.16 (m, 4H), 1.84-1.81 (m, 2H), 1.69 (dt, J=16.5, 8.1Hz, 1H). 13 C NMR (151MHz, CDCl3) δ167.9, 158.9, 158.6, 153.5, 139.7, 135.3, 135.3, 132.6, 131.0, 130.6, 129.8, 129.4, 128.5 , 125.9, 124.1, 121.6, 120.9, 113.6, 113.6, 113.5, 55.3, 55.3, 53.5, 41.1, 35.3, 34.6, 25.3, 24.8.HRMS (ESI) m / z: calcd.for 514.1874, found: 514.1864. (c 0.31, CHCl3) for 84% ee.
[0212] Example 10
[0213] This embodiment provides a compound M10. The preparation method of the compound M10 is different from that of the embodiment 1 only in that the reaction temperature is -60°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0214]
[0215] Colorless oil, yield 94%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =13.19min(minor), t R =20.85min (major), er=0.5:99.5. 1 H NMR (600MHz, CDCl3) δ7.87 (d, J=8.1Hz, 1H), 7.75 (d, J=8.0Hz, 1H), 7.43 (t, J=7.7Hz, 1H), 7.31 (t, J =7.6Hz, 1H), 7.12 (d, J = 8.8Hz, 2H), 7.08 (d, J = 8.5Hz, 2H), 6.87 (d, J = 8.6Hz, 2H), 6.77 (d, J = 8.8Hz, 2H), 5.92 (d, J=10.0Hz, 1H), 4.56 (dd, J=9.5, 7.0Hz, 1H), 4.33 (q, J=7.0Hz, 1H), 4.05 (t, J=8.2Hz, 1 H), 3.86 (dd, J=9.5, 6.6Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (t, J=8.2Hz, 1H), 3.09-3.03 (m, 1H). 13 CNMR (151MHz, CDCl3) δ165.7, 159.2, 159.0, 153.3, 144.5, 135.5, 134.7, 131.7, 131.0, 128.5, 1 26.2, 124.5, 124.4, 121.7, 121.1, 113.8, 113.6, 74.8, 73.3, 55.4, 55.3, 51.6, 46.0.HRMS (ESI): Calculate for 476.1354, found: 476.1349. (c 1.0, CHCl3) for 99% ee.
[0216] Embodiment 11
[0217] This embodiment provides a compound M11. The preparation method of the compound M11 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0218]
[0219] Colorless oil, yield 81%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =5.98min(minor), t R =6.70min(major),er=6.0:94.0. 1 H NMR (600MHz, CDCl3) δ7.87 (d, J=8.3Hz, 1H), 7.75 (d, J=7.4Hz, 1H), 7.43 (t, J=8.3Hz, 1H), 7.31 (t, J=8.2Hz, 1H), 7.14 (d, J=7.6Hz, 2H), 7.09 (d, J=8.3Hz, 2H), 7.05-7.03 (m, 4H), 5.99 (d, J=10 .0Hz, 1H), 4.57 (dd, J=9.5, 7.0Hz, 1H), 4.35-4.31 (m, 1H), 4.05 (dd, J=8.7, 7.7Hz, 1H), 3.86 (d d, J=9.4, 6.6Hz, 1H), 3.70 (dd, J=8.7, 7.7Hz, 1H), 3.08-3.03 (m, 1H), 2.37 (s, 3H), 2.31 (s, 3H). 13 C NMR (151MHz, CDCl3) δ165.7, 153.3, 145.3, 139.0, 137.4, 137.1, 136.4, 135.5, 129.7, 129.1, 12 8.9, 127.2, 126.2, 125.3, 124.5, 121.7, 121.1, 74.8, 73.2, 51.5, 45.9, 21.3, 21.1.HRMS (ESI): Calculate for 444.1456, found: 444.1454. (c 0.2, CHCl3) for 88% ee.
[0220] Example 12
[0221] This embodiment provides a compound M12. The preparation method of the compound M12 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0222]
[0223] Colorless oil, yield 89%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =14.68min(minor), t R =19.76min (major), er=5.0:95.0. 1 H NMR (600MHz, CDCl3) δ7.87 (d, J=8.2Hz, 1H), 7.75 (d, J=8.0Hz, 1H), 7.42 (t, J=7.1Hz, 1H), 7.30 (t, J=7.6Hz, 1H), 6.78-6.59 (m, 6H), 5.97-5.89 (m, 5 H), 4.56 (dd, J=9.4, 7.1Hz, 1H), 4.31 (q, J=7.2Hz, 1H), 4.06 (t, J=8.2Hz, 1 H), 3.87 (dd, J=9.4, 6.7Hz, 1H), 3.69 (t, J=8.3Hz, 1H), 3.11-3.06 (m, 1H). 13 C NMR (151MHz, CDCl3) δ165.6, 153.2, 147.7, 147.7, 147.2, 147.0, 144.5, 136.1, 135.4, 133.0, 126.2, 125.1, 124.5, 123.2, 121.7, 121.3, 121.0, 110.1, 108.2, 107.9, 107.6, 101.1, 74.7, 73.1, 51.4, 46.0.HRMS (ESI): Calculate for 504.0939, found: 504.0932. (c 0.6, CHCl3) for 90% ee.
[0224] Embodiment 13
[0225] This embodiment provides a compound M13. The preparation method of the compound M13 is different from that of the embodiment 1 only in that the reaction temperature is -60°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0226]
[0227] Colorless oil, yield 86%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =5.70min(major), t R =7.13min (minor), er=94.0:6.0. 1 H NMR (600MHz, CDCl3) δ7.89 (d, J=7.9Hz, 1H), 7.73 (d, J=8.0Hz, 1H), 7.44-7.4 1(m, 1H), 7.32-7.29(m, 1H), 7.10-7.08(m, 4H), 6.78(d, J=8.2Hz, 2H), 6.74( d, J=8.8Hz, 2H), 5.85 (d, J=10.3Hz, 1H), 4.11-4.04 (m, 2H), 3.90 (dd, J=12.0 , 8.8Hz, 1H), 3.80-3.73(m, 8H), 2.74-2.68(m, 1H), 1.39(s, 3H), 1.33(s, 3H). 13 C NMR (151MHz, CDCl3) δ165.5, 159.2, 158.7, 153.3, 144.5, 135.5, 135.0, 132.0, 130.7, 128.5, 126.1, 124. 7, 124.4, 121.8, 121.0, 113.8, 113.5, 101.6, 64.3, 63.7, 55.3, 55.2, 53.2, 44.9, 24.8, 24.8.HRMS (ESI): Calculate for 534.1773, found: 534.1787. (c 0.34, CHCl3) for 88% ee.
[0228] Embodiment 14
[0229] This embodiment provides a compound M14. The preparation method of the compound M14 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0230]
[0231] Colorless oil, yield 75%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =4.82min(minor), t R =5.56min (major), er=6.0:94.0. 1 H NMR (600MHz, CDCl3) δ7.86 (d, J=8.1Hz, 1H), 7.72 (d, J=8.0Hz, 1H), 7.43 (t, J=7.6Hz, 1H), 7.31 (t , J=7.6Hz, 1H), 7.15 (d, J=8.7Hz, 2H), 7.10 (d, J=8.6Hz, 2H), 6.79 (d, J=8.8Hz, 2H), 6.68 (d, J=8.6 Hz, 2H), 6.24 (d, J=10.3Hz, 1H), 4.55 (d, J=11.9Hz, 1H), 4.38 (d, J=11.7Hz, 1H), 4.26-4.19 (m, 2H ), 3.85 (dd, J=11.8, 5.1Hz, 1H), 3.79 (s, 3H), 3.65 (s, 3H), 3.02-2.98 (m, 1H), 1.18-1.05 (m, 14H). 13 C NMR (151MHz, CDCl3) δ165.7, 159.2, 158.7, 153.3, 143.5, 135.7, 135.5, 132.0, 130.8, 128.6, 126.0, 124.5, 124.4 , 121.7, 121.0, 113.7, 113.6, 64.9, 64.2, 55.8, 55.3, 55.1, 45.2, 17.7, 17.5, 17.5, 17.4, 12.4, 12.2.HRMS (ESI): Calculate for 606.2168, found: 606.2192. (c 0.55, CHCl3) for 88% ee.
[0232] Embodiment 15
[0233] This embodiment provides a compound M15. The preparation method of the compound M15 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0234]
[0235] Colorless oil, yield 61%. The enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=95 / 5, flow rate=0.5 mL / min, λ=254 nm.t R =3.76min(minor), t R =4.08min (major), er=7.5:92.5. 1 H NMR (600MHz, CDCl3) δ7.83 (d, J=9.1Hz, 1H), 7.74 (d, J=7.5Hz, 1H), 7.40 (t, J=8.3Hz, 1H), 7.29 (t, J=8.2Hz , 1H), 7.18 (d, J=7.8Hz, 2H), 7.14 (d, J=8.0Hz, 2H), 6.88 (d, J=8.0Hz, 2H), 6.79 (d, J=8.6Hz, 2H), 5.79 (d, J= 10.5Hz, 1H), 4.45 (dd, J=8.6, 3.5Hz, 1H), 3.98 (dd, J=10.4, 4.8Hz, 1H), 3.87-3.79 (m, 8H), 3.71 (dd, J=9.9, 5.5Hz, 1H), 3.36-3.32 (m, 1H), 0.85 (s, 9H), 0.81 (s, 9H), 0.05 (s, 3H), 0.01 (s, 3H), -0.03 (d, J=3.7Hz, 6H). 13 C NMR (151MHz, CDCl3) δ166.9, 159.1, 158.8, 153.4, 145.1, 135.6, 135.5, 132.3, 131.0, 128.6, 125.9, 124.1, 124.0, 121. 6, 120.9, 113.7, 113.5, 64.3, 64.1, 55.3, 55.2, 52.5, 41.8, 26.0, 25.9, 18.3, 18.2, -5.1, -5.3, -5.4, -5.4.HRMS (ESI): Calculate for 722.3189, found: 722.3207. (c 0.7, CHCl3) for 85% ee.
[0236] Example 16
[0237] This embodiment provides a compound M16. The preparation method of the compound M16 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0238]
[0239] Colorless oil, yield 37%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA = 90 / 10, flow rate = 0.5 mL / min, λ = 254 nm.t R =12.02min(minor),t R =13.50min(major),er=18.5:81.5. 1 H NMR (600MHz, CDCl3) δ7.87 (d, J = 8.1Hz, 1H), 7.74 (d, J = 7.9Hz, 1H), 7.43 (t, J = 7. 1Hz,1H),7.31(t,J=7.0Hz,1H),7.26–7.21(m,8H),7.17–7.12(m,6H),6.82(d,J= 8.5Hz,2H),6.79(d,J=8.7Hz,2H),5.85(d,J=10.5Hz,1H),4.66–4.63(m,1H),4. 48–4.40 (m, 4H), 3.84–3.71m, 9H), 3.62 (dd, J=9.6, 5.6Hz1H), 3.51–3.47 (m, 1H). 13 C NMR (151MHz, CDCl3) δ166.5,159.2,158.8,153.3,145.2,138.4,138.2,135.6,135.4,132.1,131.0,128.7,128.3,128.2,127. 7,127.5,127.4,126.0,124.3,123.6,121.8,121.0,113.7,113.5,73.0,72.8,71.5,71.3,55.4,55.2,50.6,40.5.HRMS(ESI): Calculate for 674.2399,found:674.2418 (c 0.17, CHCl3) for 63% ee.
[0240] Embodiment 17
[0241] This embodiment provides a compound M17. The preparation method of the compound M17 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0242]
[0243] Colorless oil, yield 85%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA = 95 / 5, flow rate = 0.5 mL / min, λ = 254 nm.t R =15.19min(minor),t R =17.48min(major),er=1.0:99.0. 1 H NMR (600MHz, CDCl3) δ7.88 (dd, J=15.9, 8.1Hz, 1H), 7.74 (t, J=8.1Hz, 1H), 7.4 6–7.41(m,1H),7.31(q,J=7.6Hz,1H),7.10-7.04(m,4H),6.86(d,J=8.3Hz,2H) , 6.71(t , J=8.8Hz , 2H), 5.84(d, J=9.9Hz, 1H), 4.36–4.26(m, 1.5H), 4.16(dd, J=11.2, 7.7Hz, 0.5H), 3.80(s, 3H), 3.75( s,3H),3.75–3.71(m,0.5H),3.61–3.58(m,0.5H),3.37-3.27(m,2H),3.10–3.01(m,1H),1.45(s,9H). 13 C NMR (151MHz, CDCl3) δ165.3,165.0,159.2,158.9,154.1,153.2,145.4,145.0,135.5,134.5,131.8,131.8,130.8,128.5,128.2,126.2,124. 5,124.2,123.9,121.8,121.7,121.1,113.8,113.5,113.2,79.8,55.3 ,55.3,52.2,51.9,51.2,50.8,50.4,49.944.9,44.3,28.6.HRMS(ESI): calcdfor 575.2038,found:575.2037. (c0.5, CHCl3) for 98% ee.
[0244] Embodiment 18
[0245] This embodiment provides a compound M18. The preparation method of the compound M18 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0246]
[0247] Colorless oil, yield 33%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA = 90 / 10, flow rate = 0.5 mL / min, λ = 254 nm.t R =14.85min(minor),t R =16.21min(major),er=3.0:97.0. 1 H NMR (600MHz, CDCl3) δ7.87 (d, J = 8.1Hz, 1H), 7.75 (d, J = 8.0Hz, 1H), 7.44 (t, J = 7.1Hz, 1H ), 7.32 (t, J = 7.1Hz, 1H), 7.10 (d, J = 8.5Hz, 2H), 7.07 (d, J = 8.8Hz, 2H), 6.86 (d, J = 8.2Hz ,2H),6.73(d,J=8.8Hz,2H),5.85(d,J=9.8Hz,1H),4.60(s,1H),4.35–4.31(m,1H),3.9 0–3.86(m,1H),3.80(s,3H),3.76(s,3H),3.58–3.51(m,2H),3.01(s,1H),1.26(s,9H). 13 C NMR (151MHz, CDCl3) δ176.4,165.0,159.3,158.9,153.1,145.4,135.4,134.4,131.7,130.8,128. 5, 126.2, 124.6, 123.7, 121.7, 121.1, 113.8, 113.5, 55.3, 55.2, 53.8, 52.939.0, 27.5.HRMS (ESI): Calculate for 559.2089 found:559.2107. (c 0.1, CHCl3) for 94% ee.
[0248] Embodiment 19
[0249] This embodiment provides a compound M19. The preparation method of the compound M19 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0250]
[0251] Colorless oil, yield 50%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=60 / 40, flow rate=0.5 mL / min, λ=254 nm.t R =9.53min(major), t R =15.40min (minor), er=94.0:6.0. 1 H NMR (600MHz, CDCl3) δ7.83 (d, J=8.3Hz, 1H), 7.73 (t, J=7.8Hz, 3H), 7.46-7.43 (m, 1H), 7.34-7.31 (m , 3H), 7.00 (dd, J=8.7, 5.0Hz, 4H), 6.83 (d, J=8.6Hz, 2H), 6.72 (d, J=8.8Hz, 2H), 5.65 (d, J=9.8Hz, 1H ), 4.18 (dd, J=10.9, 7.5Hz, 1H), 4.10-4.06 (m, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 3.58 (dd, J=10.2, 7.7 Hz, 1H), 3.34 (dd, J=10.9, 7.9Hz, 1H), 3.17 (dd, J=10.2, 8.3Hz, 1H), 2.95-2.89 (m, 1H), 2.46 (s, 3H). 13 C NMR (151MHz, CDCl3) δ164.6, 159.4, 159.0, 153.1, 145.5, 143.9, 135.4, 134.2, 133.6, 131.4, 130.7, 129.9, 128. 5, 127.7, 126.2, 124.7, 123.1, 121.7, 121.1, 113.9, 113.5, 55.4, 55.3, 54.1, 52.9, 50.2, 44.4, 21.7.HRMS (ESI): Calculate for 629.1602, found: 629.1621. (c 0.7, CHCl3) for 88% ee.
[0252] Embodiment 20
[0253] This embodiment provides a compound M20. The preparation method of the compound M20 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0254]
[0255] Colorless oil, yield 76%. The enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=60 / 40, flow rate=0.5 mL / min, λ=254 nm.t R =19.96min(major), t R =22.61min (minor), er=98.5:1.5. 1 H NMR (600MHz, CDCl3) δ8.35 (d, J=8.5Hz, 2H), 7.99 (d, J=8.8Hz, 2H), 7.81 (d, J=7.6Hz, 1H), 7.74 (d, J=7.3Hz, 1H), 7.45 (ddd, J=8.3, 7.3, 1.2Hz, 1H), 7.33 (ddd, J=8.3, 7.2, 1.2Hz, 1H), 7.02-6.99 (m, 4H), 6.83 (d, J=8.8Hz, 2H), 6. 72 (d, J=8.9Hz, 2H), 5.66 (d, J=9.8Hz, 1H), 4.23 (dd, J=11.0, 7.3Hz, 1H), 4.16-4.12 (m, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.61 (dd, J=10.4, 7.6Hz, 1H), 3.42 (dd, J=11.0, 7.6Hz, 1H), 3.24 (dd, J=10.4, 8.2Hz, 1H), 2.96-2.90 (m, 1H). 13 C NMR (151MHz, CDCl3) δ164.0, 159.5, 159.1, 153.0, 150.3, 146.1, 142.7, 135.4, 133.9, 131.3, 130.6, 128.7, 12 8.5, 126.4, 124.8, 124.5, 122.2, 121.7, 121.2, 113.9, 113.6, 55.3, 55.3, 54.1, 52.9, 50.1, 44.2.HRMS (ESI): Calculate for 660.1297 found: 660.1281. (c 1.0, CHCl3) for 97% ee.
[0256] Embodiment 21
[0257] This embodiment provides a compound M21. The preparation method of the compound M21 is different from that of Embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0258]
[0259] Colorless oil, yield 81%. HRMS (ESI): Calculate for 741.4124, found: 741.4106.
[0260] Embodiment 22
[0261] This embodiment provides a compound M22. The preparation method of the compound M22 is different from that of the embodiment 1 only in that the reaction temperature is -80°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0262]
[0263] Colorless oil, yield 61%. HRMS (ESI): Calculate for 863.3012, found: 863.3003.
[0264] Embodiment 23
[0265] This embodiment provides a compound M23. The preparation method of the compound M23 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0266]
[0267] Colorless oil, yield 45%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =9.47min(minor), t R =12.20min(major),er=30.0:70.0. 1H NMR (600MHz, CDCl3) δ7.63 (d, J=8.0Hz, 1H), 7.44 (d, J=6.8Hz, 1H), 7.22 (t, J=7.9Hz, 1H), 7.1 3 (d, J=8.8Hz, 2H), 7.08 (d, J=8.6Hz, 2H), 6.88 (d, J=8.6Hz, 2H), 6.77 (d, J=8.8Hz, 2H), 5.94 (d , J=10.0Hz, 1H), 4.63 (dd, J=9.5, 7.1Hz, 1H), 4.36 (q, J=7.2Hz, 1H), 4.05 (t, J=8.2Hz, 1H), 3. 87 (dd, J=9.5, 6.8Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.71 (t, J=8.3Hz, 1H), 3.09-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ167.3, 159.3, 159.0, 150.2, 144.6, 136.8, 134.6, 131.7, 131.0, 128.5, 12 6.5, 126.5, 125.0, 124.2, 119.5, 113.8, 113.6, 74.7, 73.2, 55.4, 55.3, 51.7, 46.0.HRMS (ESI): Calculate for 510.0964, found: 510.0981.
[0268] Embodiment 24
[0269] This embodiment provides a compound M24. The preparation method of the compound M24 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0270]
[0271] Colorless oil, yield 80%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =13.94min(minor), t R =23.11min (major), er=4.0:96.0. 1H NMR (600MHz, CDCl3) δ7.84 (d, J=2.0Hz, 1H), 7.63 (d, J=8.5Hz, 1H), 7.27 (dd, J=8.5, 2.0Hz, 1H ), 7.13 (d, J = 8.8Hz, 2H), 7.07 (d, J = 8.6Hz, 2H), 6.88 (d, J = 8.7Hz, 2H), 6.78 (d, J = 8.8Hz, 2H), 5.92 (d, J=10.0Hz, 1H), 4.55 (dd, J=9.5, 7.0Hz, 1H), 4.31 (q, J=7.0Hz, 1H), 4.07-4.04 (m, 1H) , 3.86 (dd, J=9.5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.71-3.68 (m, 1H), 3.10-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ168.0, 159.2, 158.9, 154.0, 144.6, 134.5, 133.7, 132.2, 131.7, 130.9, 12 8.5, 124.8, 124.2, 121.6, 121.6, 113.8, 113.6, 74.6, 73.2, 55.3, 55.3, 51.6, 45.9.HRMS (ESI): calcdfor 510.0964, found: 510.0978. (c 0.4, CHCl3) for 92% ee.
[0272] Embodiment 25
[0273] This embodiment provides a compound M25. The preparation method of the compound M25 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0274]
[0275] Colorless oil, yield 84%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =11.12min(minor), t R =19.22min (major), er=0.5:99.5. 1H NMR (600MHz, CDCl3) δ7.75 (d, J=8.6Hz, 1H), 7.71 (d, J=2.1Hz, 1H), 7.38 (dd, J=8.7, 2.1Hz, 1H), 7. 13 (d, J=8.8Hz, 2H), 7.07 (d, J=8.6Hz, 2H), 6.87 (d, J=8.6Hz, 2H), 6.78 (d, J=8.9Hz, 2H), 5.91 (d, J =10.0Hz, 1H), 4.55 (dd, J=9.5, 7.0Hz, 1H), 4.30 (q, J=6.9Hz, 1H), 4.06 (dd, J=8.7, 7.6Hz, 1H), 3.8 6 (dd, J=9.5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (dd, J=8.8, 7.7Hz, 1H), 3.10-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ166.4, 159.3, 159.0, 151.8, 144.6, 136.6, 134.6, 131.7, 130.9, 130.3, 12 8.5, 126.9, 124.2, 122.3, 120.7, 113.8, 113.6, 74.6, 73.2, 55.3, 55.3, 51.6, 45.9.HRMS (ESI): Calculate for 510.0964, found: 510.0973. (c0.13, CHCl3) for 99% ee.
[0276] Embodiment 26
[0277] This embodiment provides a compound M26. The preparation method of the compound M26 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0278]
[0279] Colorless oil, yield 54%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =9.76min(major), t R =13.66min (minor), er=2.0:98.0. 1H NMR (600MHz, CDCl3) δ7.74 (d, J=9.0Hz, 1H), 7.37 (t, J=8.0Hz, 1H), 7.29 (dd, J=7.8, 1.0Hz, 1H), 7 .13 (d, J=8.9Hz, 2H), 7.07 (d, J=8.6Hz, 2H), 6.87 (d, J=8.6Hz, 2H), 6.77 (d, J=8.9Hz, 2H), 5.91 (d, J=10.0Hz, 1H), 4.56 (dd, J=9.5, 7.0Hz, 1H), 4.32-4.28 (m, 1H), 4.06 (dd, J=8.8, 7.7Hz, 1H), 3.86 (dd, J=9.5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (dd, J=8.8, 7.6Hz, 1H), 3.09-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ166.9, 159.3, 159.0, 153.9, 144.6, 135.6, 134.6, 131.7, 130.9, 128.5, 12 7.1, 126.3, 124.2, 124.2, 119.9, 113.8, 113.6, 74.7, 73.3, 55.4, 55.3, 51.7, 45.9.HRMS (ESI): Calculate for 510.0964, found: 510.0970. (c 0.31, CHCl3) for 96% ee.
[0280] Embodiment 27
[0281] This embodiment provides a compound M27. The preparation method of the compound M27 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0282]
[0283] Colorless oil, yield 76%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =10.86min(minor), t R =16.39min (major), er=0.5:99.5. 1H NMR (600MHz, CDCl3) δ7.65 (dd, J=9.0, 5.1Hz, 1H), 7.54 (d, J=9.5Hz, 1H), 7.13 (d, J=8. 8Hz, 2H), 7.09-7.06 (m, 3H), 6.88 (d, J=8.6Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 5.91 (d, J=1 0.0Hz, 1H), 4.57-4.54 (m, 1H), 4.30 (q, J=7.1Hz, 1H), 4.06 (t, J=8.2Hz, 1H), 3.86 (dd, J=9.4, 6.8Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.69 (t, J=8.3Hz, 1H), 3.09-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ168.5, 162.7, 161.1, 159.3, 159.0, 154.2, 154.1, 144.6, 134.6, 131.7, 130.9, 130.8, 130 .7, 128.5, 124.2, 121.6, 121.6, 113.8, 113.6, 112.9, 112.8, 108.3, 108.1, 74.7, 73.2, 55.4, 55.3, 51.6, 45.9. 19 F NMR(565MHz, CDCl3)δ-116.10.HRMS(ESI): Calculate for 494.1260, found: 494.1264. (c 0.1, CHCl3) for 99% ee.
[0284] Embodiment 28
[0285] This embodiment provides a compound M28. The preparation method of the compound M28 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0286]
[0287] Colorless oil, yield 72%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =12.78min(minor), t R =20.44min (major), er=0.5:99.5.1 H NMR (600MHz, CDCl3) δ7.87 (d, J=1.9Hz, 1H), 7.70 (d, J=8.7Hz, 1H), 7.52 (dd, J=8.6, 2.0Hz, 1H), 7. 12 (d, J=8.8Hz, 2H), 7.07 (d, J=8.6Hz, 2H), 6.87 (d, J=8.6Hz, 2H), 6.77 (d, J=8.8Hz, 2H), 5.90 (d, J =10.0Hz, 1H), 4.54 (dd, J=9.5, 7.0Hz, 1H), 4.29 (q, J=7.0Hz, 1H), 4.05 (dd, J=8.7, 7.6Hz, 1H), 3.8 6 (dd, J=9.5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.69 (dd, J=8.8, 7.7Hz, 1H), 3.09-3.04 (m, 1H). 13 C NMR (151MHz, CDCl3) δ159.3, 159.0, 152.1, 144.6, 137.1, 134.6, 131.7, 130.9, 129.6, 128.5 , 124.2, 123.6, 122.7, 117.9, 113.8, 113.6, 74.6, 73.2, 55.4, 55.3, 51.6, 45.9.HRMS (ESI): Calculate for 554.0459, found: 554.0464. (c 0.5, CHCl3) for 99% ee.
[0288] Embodiment 29
[0289] This embodiment provides a compound M29. The preparation method of the compound M29 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0290]
[0291] Colorless oil, yield 77%. Enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=60 / 40, flow rate=0.5 mL / min, λ=254 nm.t R =19.13min(major), t R =41.51min (minor), er=99.0:1.0. 1H NMR (600MHz, CDCl3) δ7.78 (d, J=8.9Hz, 1H), 7.20 (d, J=2.5Hz, 1H), 7.12 (d, J=8.8Hz, 2H), 7.06 (d, J=8 .7Hz, 2H), 7.03 (dd, J=9.0, 2.5Hz, 1H), 6.87 (d, J=8.7Hz, 2H), 6.77 (d, J=8.8Hz, 2H), 5.89 (d, J=10.0H z, 1H), 4.52 (dd, J=9.5, 7.0Hz, 1H), 4.21 (q, J=7.0Hz, 1H), 4.09-4.05 (m, 3H), 3.87 (dd, J=9.5, 6.6Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.71 (dd, J=8.7, 7.6Hz, 1H), 3.10-3.05 (m, 1H), 1.45 (t, J=7.0Hz, 3H). 13 C NMR (151MHz, CDCl3) δ162.8, 159.2, 158.9, 156.8, 147.1, 144.6, 136.6, 134.6, 131.6, 130.9, 128.5, 1 24.1, 122.1, 115.8, 113.8, 113.6, 104.8, 74.5, 73.2, 64.2, 55.3, 55.3, 52.0, 46.1, 14.9.HRMS (ESI): Calculate for 520.1616, found: 520.1628. (c 0.20, CHCl3) for 98% ee.
[0292] Embodiment 30
[0293] This embodiment provides a compound M30. The preparation method of the compound M30 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0294]
[0295] Colorless oil, yield 70%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =14.76min(minor), t R =22.81min (major), er=2.0:98.0. 1H NMR (600MHz, CDCl3) δ7.60 (dd, J=7.6, 0.8Hz, 1H), 7.43 (d, J=8.1Hz, 1H), 7.29 (td, J=7.6, 1.2Hz, 1H), 7 .26-7.23 (m, 1H), 7.14 (d, J = 8.9Hz, 2H), 7.08 (d, J = 8.6Hz, 2H), 6.87 (d, J = 8.6Hz, 2H), 6.78 (d, J = 8.8Hz, 2H), 5.92 (d, J=10.0Hz, 1H), 4.56 (dd, J=9.5, 7.0Hz, 1H), 4.23-4.19 (m, 1H), 4.07 (dd, J=8.8, 7.7Hz, 1H) , 3.89 (dd, J=9.5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (dd, J=8.8, 7.8Hz, 1H), 3.07-3.02 (m, 1H). 13 C NMR (151MHz, CDCl3) δ164.0, 159.3, 159.0, 151.9, 144.7, 141.9, 134.5, 131.6, 130.9, 128.5, 124 .4, 124.1, 124.0, 118.6, 113.8, 113.6, 110.0, 74.9, 73.3, 55.3, 55.3, 50.3, 45.8.HRMS (ESI): calcdfor 460.1583, found: 460.1598. (c 0.6, CHCl3) for 96% ee.
[0296] Embodiment 31
[0297] This embodiment provides a compound M31. The preparation method of the compound M31 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0298]
[0299] Colorless oil, yield 49%. The enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =11.12min(major), t R =13.90min (minor), er=98.0:2.0. 1H NMR (600MHz, CDCl3) δ7.56 (d, J=2.1Hz, 1H), 7.33 (d, J=8.6Hz, 1H), 7.21 (dd, J=8.6, 2.1Hz, 1H), 7.13 (d, J=8.8Hz, 2H), 7.06 (d, J=8.6Hz, 2H), 6.87 (d, J=8.6Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 5.90 (d, J=10.0Hz, 1H), 4.53 (dd, J=9.5, 7.0Hz, 1H), 4.19-4.15 (m, 1H), 4.07 (t, J=8.2Hz, 1H), 3.88 ( dd, J=9.5, 6.6Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70 (dd, J=8.8, 7.8Hz, 1H), 3.08-3.03 (m, 1H). 13 C NMR (151MHz, CDCl3) δ165.7, 159.3, 159.0, 150.4, 144.9, 143.0, 134.4, 131.6, 130.9, 130.0, 12 8.5, 124.3, 123.8, 118.6, 113.8, 113.6, 110.6, 74.7, 73.3, 55.4, 55.3, 50.4, 45.7.HRMS (ESI): Calculate for 494.1193, found: 494.1186. (c 0.15, CHCl3) for 96% ee.
[0300] Embodiment 32
[0301] This embodiment provides a compound M32. The preparation method of the compound M32 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0302]
[0303] Colorless oil, yield 79%. The enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =19.42min(minor), t R =24.36min (major), er=3.0:97.0. 1H NMR (600MHz, CDCl3) δ7.38 (s, 1H), 7.29 (d, J=8.2Hz, 1H), 7.14 (d, J=8.8Hz, 2H), 7.08 (d, J=8.4 Hz, 2H), 7.05 (d, J=8.3Hz, 1H), 6.87 (d, J=8.6Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 5.91 (d, J=10.0Hz , 1H), 4.55 (dd, J=9.3, 7.1Hz, 1H), 4.19 (q, J=7.1Hz, 1H), 4.06 (t, J=8.2Hz, 1H), 3.88 (dd, J=9. 5, 6.5Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.69 (t, J=8.3Hz, 1H), 3.07-3.01 (m, 1H), 2.45 (s, 3H). 13 C NMR (151MHz, CDCl3) δ163.8, 159.3, 159.0, 150.1, 144.7, 142.1, 134.6, 134.3, 131.7, 130.9, 128. 5, 125.1, 124.1, 118.7, 113.8, 113.6, 109.3, 74.9, 73.3, 55.3, 55.3, 50.3, 45.8, 21.5.HRMS (ESI): Calculate for 474.1739, found: 474.1734. (c0.3, CHCl3) for 94% ee.
[0304] Embodiment 33
[0305] This embodiment provides a compound M33. The preparation method of the compound M33 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0306]
[0307] Colorless oil, yield 72%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =14.83min(minor), t R =16.66min (major), er=9.5:90.5. 1H NMR (600MHz, CDCl3) δ7.66 (d, J=3.4Hz, 1H), 7.21 (d, J=3.4Hz, 1H), 7.13 (d, J=8.9Hz, 2H), 7 .08 (d, J=8.7Hz, 2H), 6.91 (d, J=8.7Hz, 2H), 6.79 (d, J=8.9Hz, 2H), 5.87 (d, J=10.0Hz, 1H), 4.43 (dd, J=9.4, 7.0Hz, 1H), 4.08 (q, J=7.0Hz, 1H), 4.02 (dd, J=8.7, 7.6Hz, 1H), 3.85 (s, 3H ), 3.82 (dd, J=9.4, 6.6Hz, 1H), 3.78 (s, 3H), 3.65 (dd, J=8.7, 7.6Hz, 1H), 3.04-2.98 (m, 1H). 13 C NMR (151MHz, CDCl3) δ163.3, 159.2, 158.9, 144.3, 142.9, 134.7, 131.7, 131.0, 12 8.5, 124.5, 119.6, 113.8, 113.5, 74.6, 73.3, 55.3, 55.3, 52.4, 46.0.HRMS (ESI): Calculate for 426.1198, found: 426.1213. (c 0.15, CHCl3) for 81% ee.
[0308] Embodiment 34
[0309] This embodiment provides a compound M34. The preparation method of the compound M34 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0310]
[0311] Colorless oil, yield 61%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=60 / 40, flow rate=0.5 mL / min, λ=254 nm.t R =8.09min(minor), t R =9.30min (major), er=9.0:91.0. 1H NMR (600MHz, CDCl3) δ8.99 (s, 1H), 7.14 (d, J=7.0Hz, 2H), 7.08 (d, J=6.8Hz, 2H), 6.91 (d, J=6.8Hz, 2H), 6.79 (d, J=7.0Hz, 2H), 5.88 (d, J=10.0Hz, 1H ), 4.53 (t, J=7.4Hz, 1H), 4.30 (q, J=6.1Hz, 1H), 4.04 (t, J=8.2Hz, 1H), 3.8 8-3.85 (m, 4H), 3.78 (s, 3H), 3.65 (t, J=8.3Hz, 1H), 3.00 (p, J=7.9Hz, 1H). 13 C NMR (151MHz, CDCl3) δ159.3, 159.0, 151.6, 144.7, 134.4, 131.6, 130.9, 128.5, 123.9, 113.9, 113.6, 74.9, 73.2, 55.3, 55.3, 52.0, 46.0.HRMS (ESI): Calculate for 427.1150, found: 427.1165. (c 0.1, CHCl3) for 82% ee.
[0312] Embodiment 35
[0313] This embodiment provides a compound M35. The preparation method of the compound M35 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0314]
[0315] White solid, yield 96%. Enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =10.35min(minor), t R =15.97min (major), er=13.0:87.0. 1H NMR (600MHz, CDCl3) δ7.90 (d, J=8.6Hz, 2H), 7.46 (d, J=8.6Hz, 2H), 7.14 (d, J=8.8Hz, 2H), 7 .08 (d, J=8.6Hz, 2H), 6.91 (d, J=8.6Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 5.89 (d, J=10.0Hz, 1H), 4.51 (dd, J=9.6, 6.9Hz, 1H), 4.12 (q, J=6.9Hz, 1H), 4.07 (dd, J=8.8, 7.8Hz, 1H), 3.90 (dd, J =9.6, 6.4Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.68 (dd, J = 8.8, 7.9Hz, 1H), 3.07-3.01 (m, 1H). 13 C NMR (151MHz, CDCl3) δ165.1, 163.8, 159.3, 159.0, 145.0, 138.0, 134.3, 131.5, 130.9, 129.5 , 128.5, 128.0, 123.5, 122.0, 113.9, 113.6, 74.7, 73.3, 55.3, 55.3, 50.7, 46.1.HRMS (ESI): Calculate for 521.1302, found: 521.1317. (c 0.4, CHCl3) for 74% ee.
[0316] Embodiment 36
[0317] This embodiment provides a compound M36. The preparation method of the compound M36 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0318]
[0319] Colorless oil, yield 75%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =6.50min(major), t R =9.40min (minor), er=98.0:2.0. 1H NMR (600MHz, CDCl3) δ7.77 (d, J=8.7Hz, 1H), 7.69 (d, J=2.1Hz, 1H), 7.38 (dd, J=8.7 , 2.1Hz, 1H), 7.08 (t, J=9.2Hz, 4H), 6.79 (d, J=8.2Hz, 2H), 6.74 (d, J=8.8Hz, 2H), 5 .83 (d, J=10.3Hz, 1H), 4.08 (dd, J=12.0, 3.0Hz, 1H), 4.03-3.99 (m, 1H), 3.90 (dd, J =12.1, 8.9Hz, 1H), 3.80-3.73(m, 8H), 2.75-2.70(m, 1H), 1.39(s, 3H), 1.33(s, 3H). 13 C NMR (151MHz, CDCl3) δ166.3, 159.2, 158.8, 151.9, 144.6, 136.7, 134.9, 132.0, 130.6, 130.2, 128.5, 126. 8, 124.5, 122.3, 120.6, 113.8, 113.5, 101.6, 64.3, 63.6, 55.4, 55.2, 53.4, 44.8, 24.8, 24.7.HRMS (ESI): Calculate for 568.1383, found: 568.1395. (c 0.2, CHCl3) for 96% ee.
[0320] Embodiment 37
[0321] This embodiment provides a compound M37. The preparation method of the compound M37 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0322]
[0323] Colorless oil, yield 55%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =6.78min(major), t R =10.32min (minor), er=97.5:2.5. 1H NMR (600MHz, CDCl3) δ7.85 (d, J=2.0Hz, 1H), 7.71 (d, J=8.6Hz, 1H), 7.52 (dd, J=8. 6, 2.0Hz, 1H), 7.09-7.06 (m, 4H), 6.78 (d, J=8.1Hz, 2H), 6.74 (d, J=8.8Hz, 2H), 5.8 2 (d, J=10.3Hz, 1H), 4.08 (dd, J=12.0, 3.0Hz, 1H), 4.03-3.99 (m, 1H), 3.90 (dd, J= 12.1, 8.9Hz, 1H), 3.79-3.73(m, 8H), 2.75-2.70(m, 1H), 1.39(s, 3H), 1.32(s, 3H). 13 C NMR (151MHz, CDCl3) δ166.4, 159.2, 158.8, 152.2, 144.6, 137.1, 134.9, 132.0, 130.6, 129.5, 128.5, 124. 5, 123.5, 122.7, 117.8, 113.8, 113.5, 101.6, 64.3, 63.6, 55.4, 55.2, 53.4, 44.8, 24.8, 24.7.HRMS (ESI): Calculate for 634.0697, found: 634.0712. (c 0.4, CHCl3) for 95% ee.
[0324] Embodiment 38
[0325] This embodiment provides a compound M38. The preparation method of the compound M38 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0326]
[0327] Colorless oil, yield 83%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =6.04min(major), t R =7.48min (minor), er=94.0:6.0. 1H NMR (600MHz, CDCl3) δ7.60 (dd, J=7.6, 0.9Hz, 1H), 7.41 (d, J=7.9Hz, 1H), 7.29 (td, J=7. 6, 1.2Hz, 1H), 7.24 (td, J=7.7, 1.3Hz, 1H), 7.11 (d, J=8.8Hz, 2H), 7.08 (d, J=8.6Hz, 2H), 6.78 (d, J=8.6Hz, 2H), 6.75 (d, J=8.9Hz, 2H), 5.83 (d, J=10.3Hz, 1H), 4.08 (d, J=9.3Hz, 1H), 3.95-3.91(m, 2H), 3.80-3.73(m, 8H), 2.73-2.68(m, 1H), 1.39(s, 3H), 1.33(s, 3H). 13 C NMR (151MHz, CDCl3) δ163.8, 159.2, 158.7, 151.8, 144.8, 142.0, 134.8, 132.0, 130.6, 128.5, 124.4, 124. 4, 124.0, 118.6, 113.9, 113.5, 109.9, 101.6, 64.3, 63.8, 55.4, 55.2, 52.2, 44.8, 24.8, 24.7.HRMS (ESI): calcdfor 540.1821, found: 540.1840. (c 0.22, CHCl3) for 88% ee.
[0328] Embodiment 39
[0329] This embodiment provides a compound M39. The preparation method of the compound M39 is different from that of Embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of Embodiment 1.
[0330]
[0331] Colorless oil, yield 99%. Enantiomeric ratio was determined by HPLC analysis using ID-H (CHIRALPAK, 5 μm), Hexane / IPA=99 / 1, flow rate=0.5 mL / min, λ=254 nm.t R =4.63min(minor), t R =5.18min (major), er=2.0:98.0. 1H NMR (600MHz, CDCl3) δ7.78 (s, 1H), 7.63 (d, J = 8.5Hz, 1H), 7.25 (d, J = 1.9Hz, 1H), 7.16 (d, J = 7.3Hz , 2H), 7.12 (d, J=7.5Hz, 2H), 6.88 (d, J=7.4Hz, 2H), 6.78 (d, J=7.8Hz, 2H), 5.76 (d, J=10.6Hz, 1H), 4.46-4.44 (m, 1H), 3.95 (dd, J=10.5, 4.9Hz, 1H), 3.83-3.79 (m, 8H), 3.69 (dd, J=10.1, 5.6Hz, 1H) , 3.33-3.29 (m, 1H), 0.84 (s, 9H), 0.80 (s, 9H), 0.03 (s, 3H), -0.00 (s, 3H), -0.04 (d, J=3.6Hz, 6H). 13 C NMR (151MHz, CDCl3) δ169.4, 159.1, 158.8, 154.2, 145.1, 135.5, 133.7, 132.3, 132.0, 131.0, 128.6, 124.5, 123.9, 1 21.5, 121.4, 113.7, 113.5, 64.2, 64.0, 55.4, 55.3, 52.7, 41.8, 26.0, 25.9, 18.3, 18.2, -5.1, -5.3, -5.4, -5.4.HRMS (ESI): Calculate for 756.2800, found: 756.2823. (c 1.0, CHCl3) for 96% ee.
[0332] Embodiment 40
[0333] This embodiment provides a compound M40. The preparation method of the compound M40 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0334]
[0335] Colorless oil, yield 53%. The enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=95 / 5, flow rate=0.5 mL / min, λ=254 nm.t R =3.73min(minor), t R =4.07min (major), er=1.0:99.0.1 H NMR (600MHz, CDCl3) δ7.71-7.70 (m, 2H), 7.36 (dd, J=8.7, 2.0Hz, 1H), 7.14 (dd, J=21.9, 8.7 Hz, 4H), 6.88 (d, J=8.7Hz, 2H), 6.78 (d, J=8.8Hz, 2H), 5.77 (d, J=10.5Hz, 1H), 4.45-4.43 (m , 1H), 3.95 (dd, J=10.5, 4.8Hz, 1H), 3.84-3.79 (m, 8H), 3.70 (dd, J=10.1, 5.5Hz, 1H), 3.33- 3.29 (m, 1H), 0.84 (s, 9H), 0.80 (s, 9H), 0.03 (s, 3H), -0.00 (s, 3H), -0.04 (d, J=4.7Hz, 6H). 13 C NMR (151MHz, CDCl3) δ167.8, 159.1, 158.8, 151.9, 145.1, 136.7, 135.5, 132.3, 131.0, 129.9, 128.6, 126.6, 123.8, 122. 1, 120.6, 113.7, 113.5, 64.2, 64.0, 55.3, 55.3, 52.7, 41.9, 26.0, 25.9, 18.3, 18.2, -5.1, -5.3, -5.4, -5.5.HRMS (ESI): Calculate for 756.2800, found: 756.2813. (c 0.4, CHCl3) for 98% ee.
[0336] Embodiment 41
[0337] This embodiment provides a compound M41. The preparation method of the compound M41 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0338]
[0339] Colorless oil, yield 99%. Enantiomeric ratio was determined by HPLC analysis using IG-H (CHIRALPAK, 5 μm), Hexane / IPA=95 / 5, flow rate=0.5 mL / min, λ=254 nm.t R =3.66min(minor), t R =3.96min (major), er=1.5:98.5. 1H NMR (600MHz, CDCl3) δ7.70 (d, J=8.1Hz, 1H), 7.34 (t, J=7.9Hz, 1H), 7.27 (d, J=7.6Hz, 1H), 7.16 (d, J= 8.6Hz, 2H), 7.13 (d, J=8.8Hz, 2H), 6.88 (d, J=8.7Hz, 2H), 6.79 (d, J=8.8Hz, 2H), 5.77 (d, J=10.5Hz, 1 H), 4.48-4.45 (m, 1H), 3.96 (dd, J=10.5, 4.9Hz, 1H), 3.81 (d, J=19.8Hz, 8H), 3.69 (dd, J=10.1, 5.4Hz , 1H), 3.34-3.29 (m, 1H), 0.84 (s, 9H), 0.81 (s, 9H), 0.04 (s, 3H), 0.00 (s, 3H), -0.04 (d, J=3.4Hz, 6H). 13 C NMR (151MHz, CDCl3) δ168.2, 159.1, 158.8, 154.0, 145.2, 135.6, 135.5, 132.3, 131.0, 128.6, 126.9, 126.2, 123.8, 123. 7, 119.7, 113.7, 113.5, 64.3, 64.0, 55.4, 55.3, 52.8, 41.9, 26.0, 25.9, 18.3, 18.2, -5.1, -5.3, -5.4, -5.4.HRMS (ESI): Calculate for 756.2800, found: 756.2820. (c 0.23, CHCl3) for 97% ee.
[0340] Embodiment 42
[0341] This embodiment provides a compound M42. The preparation method of the compound M42 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0342]
[0343] Colorless oil, yield 90%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=80 / 20, flow rate=0.5 mL / min, λ=254 nm.t R =8.16min(minor), t R=8.78min (major), er=0.5:99.5. 1 H NMR (600MHz, CDCl3) δ7.85 (d, J=14.7Hz, 1H), 7.63 (t, J=7.8Hz, 1H), 7.28 (d, J=7.4Hz, 1H ), 7.06 (d, J = 7.4Hz, 4H), 6.86 (d, J = 8.2Hz, 2H), 6.72 (d, J = 8.6Hz, 2H), 5.84 (d, J = 10.2Hz, 1H), 4.31-4.24 (m, 1.5H), 4.14 (dd, J=11.2, 7.7Hz, 0.5H), 3.81 (s, 3H), 3.76 (s, 3H), 3.75 -3.71(m, 0.5H), 3.62-3.59(m, 0.5H), 3.37-3.28(m, 2H), 3.13-3.04(m, 1H), 1.47(s, 9H). 13 C NMR (151MHz, CDCl3) δ167.5, 167.3, 159.3, 158.9, 154.0, 154.0, 145.4, 145.0, 134.4, 133.6, 132.3, 131.8, 130.8, 128.5, 12 4.8, 124.0, 123.8, 121.6, 113.8, 113.5, 79.9, 55.3, 55.3, 52.0, 51.6, 51.1, 50.8, 50.5, 50.0, 44.8, 44.1, 28.6.HRMS (ESI): Calculate for 631.1468 found: 631.1489. (c 0.6, CHCl3) for 99% ee.
[0344] Embodiment 43
[0345] This embodiment provides a compound M43. The preparation method of the compound M43 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0346]
[0347] Colorless oil, yield 64%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =9.78min(minor), t R=11.42min (major), er=0.5:99.5. 1 H NMR (600MHz, CDCl3) δ7.76 (dd, J=15.0, 8.6Hz, 1H), 7.69 (d, J=6.7Hz, 1H), 7.39-7.37 (m, 1H ), 7.07 (q, J=9.1Hz, 4H), 6.86 (dd, J=8.6, 3.8Hz, 2H), 6.72 (t, J=8.7Hz, 2H), 5.83 (d, J=9.9 Hz, 1H), 4.32-4.25 (m, 1.5H), 4.14 (dd, J=11.2, 7.7Hz, 0.5H), 3.80 (s, 3H), 3.75 (s, 3H), 3. 75-3.72(m, 0.5H), 3.62-3.59(m, 0.5H), 3.37-3.28(m, 2H), 3.12-3.04(m, 1H), 1.47(s, 9H). 13 C NMR (151MHz, CDCl3) δ165.9, 165.7, 159.3, 158.9, 154.0, 151.8, 145.4, 145.0, 136.6, 134.4, 131.8, 130.8, 130.4, 128.5, 126.9 , 124.0, 123.8, 122.3, 120.7, 113.8, 113.5, 79.9, 55.3, 55.2, 52.0, 51.8, 51.1, 50.8, 50.5, 50.0, 44.7, 44.1, 28.5.HRMS (ESI): Calculate for 631.1468 found: 631.1488. (c 0.36, CHCl3) for 99% ee.
[0348] Embodiment 44
[0349] This embodiment provides a compound M44. The preparation method of the compound M44 is different from that of the embodiment 1 only in that the reaction temperature is -40°C, the reaction time is 12 hours, and the other steps are the same as those of the embodiment 1.
[0350]
[0351] Colorless oil, yield 73%. The enantiomeric ratio was determined by HPLC analysis using OD-H (CHIRALPAK, 5 μm), Hexane / IPA=90 / 10, flow rate=0.5 mL / min, λ=254 nm.t R =8.60min(minor), tR =11.68min (major), er=1.0:99.0. 1 H NMR (600MHz, CDCl3) δ7.76 (dd, J=14.8, 8.1Hz, 1H), 7.37 (q, J=9.4, 8.7Hz, 1H), 7.30 (d, J=7. 2Hz, 1H), 7.08 (d, J=7.5Hz, 4H), 6.87 (dd, J=5.9, 3.0Hz, 2H), 6.75-6.72 (m, 2H), 5.85 (d, J=9 .2Hz, 1H), 4.31-4.26 (m, 1.5H), 4.15 (dd, J=11.2, 7.7Hz, 0.5H), 3.81 (s, 3H), 3.76 (s, 3H), 3 .76-3.72(m, 0.5H), 3.63-3.59(m, 0.5H), 3.39-3.28(m, 2H), 3.12-3.04(m, 1H), 1.47(s, 9H). 13 C NMR (151MHz, CDCl3) δ166.4, 166.2, 159.3, 158.9, 154.0, 153.8, 145.5, 145.1, 135.5, 134.5, 131.8, 130.8, 128.5, 128.2, 127.1, 126.3, 12 4.2, 124.0, 123.8, 120.0, 119.9, 113.8, 113.5, 113.2, 79.9, 55.3, 55.3, 52.0, 51.8, 51.1, 50.8, 50.5, 50.0, 44.7, 44.1, 28.6.HRMS (ESI): Calculate for 631.1468 found: 631.1495. (c 0.2, CHCl3) for 98% ee.
[0352] Embodiment 45
[0353] This embodiment provides a compound M45, and the preparation method of the compound M45 comprises the following steps:
[0354]
[0355] Compound M10 (0.2 mmol, 95 mg) was dissolved in ethanol (2 mL) and acetonitrile (0.5 mL), and (NH4)6Mo7O 244H2O (50 mg, 4.0 mmol) in H2O2 (150 uL, 30 wt.%, 1.6 mmol, 8.0 equiv) water solution was stirred at room temperature for 12 hours. The reaction was then quenched with sodium sulfite (0.5 mL, 2 M), further diluted with water (5 mL), and extracted with ethyl acetate (3×10 mL). The organic layers were combined, washed with brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and purified by column chromatography (PE / EA=5 / 1) to give compound M45.
[0356] Colorless oil, yield 84%. The enantiomeric ratio was determined by HPLC analysis using AD-H (CHIRALPAK, 5 μm), Hexane / IPA=60 / 40, flow rate=0.5 mL / min, λ=254 nm.t R =12.24min(minor), t R =13.87min (major), er=2.0:98.0. 1 H NMR (600MHz, CDCl3) δ8.19 (d, J=8.1Hz, 1H), 7.94 (d, J=7.7Hz, 1H), 7.59 (dt, J=25.3, 7.2Hz, 2H) , 6.91 (d, J=6.9Hz, 2H), 6.73 (s, 4H), 6.70 (d, J=7.0Hz, 2H), 5.69 (d, J=10.0Hz, 1H), 4.55-4.51 (m 1H), 4.30-4.26(m, 2H), 4.13-4.10(m, 1H), 3.82(s, 3H), 3.76(s, 3H), 3.64(t, J=7.8Hz, 1H), 3.60-3.55(m, 1H). 13 C NMR (151MHz, CDCl3) δ165.1, 159.3, 159.0, 152.9, 144.4, 137.0, 134.4, 130.9, 130.6, 128.6, 12 8.1, 127.7, 125.5, 123.2, 122.4, 113.7, 113.4, 74.6, 69.0, 67.4, 55.3, 55.3, 42.3.HRMS (ESI): Calculate for 508.1252, found: 508.1269. (c 1.0, CHCl3) for 96% ee.
[0357] Embodiment 46
[0358] This example provides a compound M46, and the preparation method of the compound M46 is the same as that of Example 45:
[0359]
[0360] Colorless oil, yield 81%. 1 H NMR (600MHz, CDCl3) δ7.94 (d, J=8.5Hz, 2H), 7.52 (d, J=8.5Hz, 2H), 7.05 (d, J=8.8Hz, 2H), 7.01 (d, J=8.6Hz, 2H), 6.84 (d, J=8.6Hz, 2H), 6.74 (d, J=8.8Hz, 2H), 5.76 (d, J=9. 7Hz, 1H), 4.49 (dd, J=10.8, 4.6Hz, 1H), 4.28 (dd, J=10.8, 8.1Hz, 1H), 4.19-4.16 (m, 1H ), 4.07-4.04(m, 1H), 3.79(s, 3H), 3.77(s, 3H), 3.68-3.63(m, 1H), 3.60-3.57(m, 1H). 13 C NMR (151MHz, CDCl3) δ165.9, 161.3, 159.5, 159.1, 145.4, 139.9, 133.9, 130.8, 130.7, 129.8 , 129.0, 128.5, 121.9, 120.6, 114.0, 113.6, 74.3, 70.4, 67.5, 55.3, 55.2, 41.8.HRMS (ESI): Calculate for 553.1200, found: 553.1195.
[0361] Embodiment 47
[0362] This embodiment provides a compound M1, and the preparation method of the compound M1 comprises the following steps:
[0363]
[0364] 1.00 mmol of compound 1a, 1.05 mmol of compound 2a and 3.00 mmol of TFA were added into the reactor. After the addition was completed, the reaction was stirred at -40°C under nitrogen protection for 8 hours. The reaction was terminated and column chromatography (PE / EA=10 / 1) was performed to obtain a colorless oily liquid, namely compound 3a (yield: 91%).
[0365] Tested: 1H NMR (600MHz, CDCl3) δ7.89 (d, J=8.1Hz, 1H), 7.73 (d, J=7.8Hz, 1H), 7.42 (t, J=8.3Hz, 1H), 7. 29 (t, J=8.2Hz, 1H), 7.11 (d, J=8.6Hz, 2H), 7.05 (d, J=8.8Hz, 2H), 6.88 (d, J=8.6Hz, 2H), 6.7 0 (d, J=8.8Hz, 2H), 5.89 (d, J=10.0Hz, 1H), 4.02-3.98 (m, 1H), 3.82 (s, 3H), 3.75 (s, 3H), 2.7 4-2.68(m, 1H), 2.54-2.47(m, 1H), 2.00-1.95(m, 1H), 1.86-1.74(m, 3H), 1.67-1.60(m, 1H). 13 C NMR (151MHz, CDCl3) δ167.4, 158.8, 158.6, 153.4, 142.1, 135.4, 135.3, 132.5, 131.0, 129.1, 128.4, 126.0, 124.2, 121.5, 120.9, 113.6, 113.4, 55.3, 55.2, 53.5, 47.0, 34.1, 33.3, 23.6. HRMS (ESI) m / z: calcd.for 474.1561, found: 474.156.
[0366] Embodiment 48
[0367] This example provides an example using meso-endo as a reactant (taking 1h' and 1i' as examples):
[0368]
[0369] The above experimental results show that both endo and exo type reactants can be applied to the reaction system provided by the present invention.
[0370] Test Example 1
[0371] 3CL pro Inhibitory activity
[0372] Inhibition test against coronavirus 3CL protease (SARS-CoV-1 and SARS-CoV-2) at 10 μM concentration
[0373] Test Sample: Compounds M1-M46.
[0374] Test method: 10 μL SARS-CoV-1 3CLpro or SARS-CoV-23CL pro (final concentration is 200nM) and 10μL compound solution (final concentration is 10μM) were mixed in 70μL buffer (50mM Tris-HCl, PH=7.3, 1mM EDTA), added to a 96-well black board, pre-incubated at 37°C for 60 minutes, and then 10μL fluorescent substrate (final concentration is 25μM) was added to start the reaction. The multifunctional microplate reader was used to continuously detect for 20 minutes (excitation wavelength is 340nm, emission wavelength is 490nm), and the fluorescence value of the hydrolysis product was collected. PF-07321332 was used as a positive drug, and each compound was set up for 2 repeated tests. Among them, the calculation formula for inhibiting enzyme activity is:
[0375] Inhibitory enzyme activity (%) = (RFU2-RFU1) / (RFU2-RFU0)×100
[0376] RFU2 is the fluorescence intensity value without adding the test compound (maximum enzyme activity response value), RFU1 is the fluorescence intensity value of the test compound (sample response value), and RFU0 is the fluorescence intensity value of the blank well.
[0377] The test results are shown in Table 1 below:
[0378] Table 1
[0379]
[0380] The test results show that most of the compounds provided by the present invention are effective against SARS-CoV-1 3CL pro and SARS-CoV-23CL pro All have inhibitory effects.
[0381] Test Example 2
[0382] IC 50 Value calculation
[0383] Test samples: Compound M1 and Compound M46.
[0384] Test method: 10 μL SARS-CoV-1 3CL pro or SARS-CoV-2 3CL pro(final concentration is 200nM) and 10μL of compound solution of different concentrations were mixed in 70μL buffer (50mM Tris-HCl, PH=7.3, 1mM EDTA), added to a 96-well black board, pre-incubated at 37°C for 60 minutes, and then 10μL of fluorescent substrate (final concentration is 25μM) was added to start the reaction. The multifunctional microplate reader was used to continuously detect for 20 minutes (excitation wavelength is 340nm, emission wavelength is 490nm), and the fluorescence value of the hydrolysis product was collected. PF-07321332 was used as a positive drug, and 2 repeated tests were set for each compound. The logarithm of the concentration of the compound to be tested was used as the horizontal axis, and the inhibition of enzyme activity was used as the vertical axis to draw the inhibition curve, and the data was processed by Graph Pad Prism8.0 software.
[0385] like Figure 1 As shown, compound M1 has an inhibitory effect on SARS-CoV-1 3CL pro Schematic diagram of the inhibitory effect, IC 50 The value was 5.32±0.32μM.
[0386] like Figure 2 As shown, compound M1 has an inhibitory effect on SARS-CoV-2 3CL pro Schematic diagram of the inhibitory effect, IC 50 The value was 12.44±0.84μM.
[0387] like Figure 3 As shown, compound M46 has an inhibitory effect on SARS-CoV-1 3CL pro Schematic diagram of the inhibitory effect, IC 50 The value was 0.75±0.04μM.
[0388] like Figure 4 As shown, compound M46 has an inhibitory effect on SARS-CoV-2 3CL pro Schematic diagram of the inhibitory effect, IC 50 The value was 0.98±0.12μM.
[0389] Test Example 3
[0390] Compound M46 targets SARS-CoV-2 3CL pro Research on the related mechanisms
[0391] (1) Time-dependent inhibition studies
[0392] The specific operation steps are as follows: add 10 μL of ZGS-41 of different concentrations, 10 μL of SARS-CoV-23CLpro (200 nM, final concentration) and 70 μL of buffer (50 mM Tris-HCl, PH = 7.3, 1 mM ethylenediaminetetraacetic acid) to a 96-well black board, pre-incubate at 37 ° C for 5 min, 15 min, 30 min, 45 min, 60 min, 90 min, and 120 min, respectively, and then add 10 μL of substrate Dabcyl-KNSTLQSGLRKE-Edans (25 μM, final concentration) to start the reaction, and continuously detect for 20 minutes at an excitation wavelength (λex) of 340 nm and an emission wavelength (λem) of 490 nm on a microplate reader. The inhibition curve is drawn with the logarithm of the concentration of the test compound as the horizontal axis and the residual enzyme activity as the vertical axis, and the data is processed by Graph Pad Prism 8.0 software. The calculation formula of the residual enzyme activity is: residual enzyme activity (%) = 1 - inhibitory enzyme activity (%).
[0393] Figure 5 Compound M46 for SARS-CoV-2 3CL pro Time dependence curve of IC 50 Value>10μM; pre-incubation 15min, IC 50 The value is 4.08μM; pre-incubation for 30min, IC 50 The value is 1.52μM; pre-incubation for 45min, IC 50 The value is 0.83μM; pre-incubation for 60min, IC 50 The value is 0.45μM; pre-incubation for 90min, IC 50 The value is 0.45μM; pre-incubation for 120min, IC 50 The value was 0.42 μM. Compound M46 was able to significantly lose SARS-CoV-2 3CL in a time-dependent manner pro Activity of protein.
[0394] (2) M46 against SARS-CoV-2 3CL pro Kinetic studies of proteins
[0395] Mainly targeting M46 against SARS-CoV-2 3CL pro The protein was studied kinetically using the second-order rate constant k inact / K i To characterize the strength of irreversible inhibition.
[0396] The specific operation is as follows: SARS-CoV-2 3CL proThe samples were incubated with different concentrations of compounds, and the enzyme activity at different incubation times was detected by the protease assay based on the FRET principle. The natural logarithm of the residual enzyme activity and the incubation time were plotted to obtain the k obs The absolute value of the slope of each linear curve. obs The value is the vertical axis, and nonlinear analysis was performed using Graph Pad Prism 8.0 software, and k was obtained according to the following formula inact and K i value, overall inhibition strength (K I ) is given by the second-order rate constant k inact / K i express.
[0397] k obs =k inact ×[I] / ([I]+K i )
[0398] The experimental results are as follows Figure 6 As shown, a curve chart of the natural logarithm of the residual enzyme activity and the incubation time for different concentrations of compound M46 is shown; from the figure, it can be seen that compound M46 inhibits the hydrolysis activity of the new coronavirus 3CL protease in a time- and dose-dependent manner.
[0399] like Figure 7 As shown, nonlinear analysis is performed through software, and its K i The value is 10.04 μM, k inact The value is 0.074min -1 , the inhibition kinetic constant K was calculated I 0.0074 μM -1 min -1 , showing better inhibitory ability.
[0400] The applicant declares that the present invention illustrates the process method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned process steps, that is, it does not mean that the present invention must rely on the above-mentioned process steps to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of the raw materials selected by the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A homoallyl compound, characterized in that: The homoallyl compound has a structure shown in the following formula I: wherein X is selected from sulfur or sulfonyl; R1 and R2 are each independently selected from substituted or unsubstituted C6-C12 aryl groups; the substituted substituents are each independently selected from any one of C1-C6 alkyl, C2-C6 alkoxyalkenyl, C1-C6 alkoxy, C1-C6 alkylthio, and C2-C12 heterocycloalkyl; The R3 and R4 are each independently selected from unsubstituted or R c Substituted C1-C6 alkyl, said R c Selected from OTBS or OBn; Or the R3 and R4 are connected to form a ring C m ; The ring C m Selected from unsubstituted or R d Substituted C3-C12 cycloalkyl, unsubstituted or R d Substituted C3-C12 cycloalkenyl, unsubstituted or R d Any one of the substituted C2-C12 heterocyclic groups; said R d Any one selected from C1-C6 alkyl, acyl or sulfonyl; G is selected from hydrogen or any one of the following structures: DG is selected from any one of hydrogen, halogen, unsubstituted C1-C6 alkyl, unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C12 aryl; the substituted substituent is selected from halogen; Indicates whether a chemical bond is in cis or trans configuration; Indicates the attachment site of a group.
2. A homoallyl compound, characterized in that: The homoallyl compound is selected from any one of the structures shown in the following M1-M46:
3. An enantiomer, diastereomer or pharmaceutically acceptable salt thereof of the homoallyl compound according to claim 1 or 2.
4. The enantiomer, diastereomer or pharmaceutically acceptable salt of the homoallyl compound according to claim 3, characterized in that: The pharmaceutically acceptable salt includes any one or a combination of at least two of hydrochloride, hydrobromide, phosphate, sulfate, methanesulfonate, p-toluenesulfonate, acetate, trifluoroacetate, salicylate, amino acid salt, citrate, maleate, tartrate, fumarate, citrate, lactate, sodium salt, potassium salt, calcium salt, magnesium salt, lithium salt, ammonium salt or a salt of an organic base that can provide a physiologically acceptable cation.
5. The enantiomer, diastereomer or pharmaceutically acceptable salt of the homoallyl compound according to claim 4, characterized in that: The salt of the organic base that can provide a physiologically acceptable cation includes any one of methylamine salt, dimethylamine salt, trimethylamine salt, piperidine salt, morpholine salt or tris(2-hydroxyethyl)amine salt or a combination of at least two thereof.
6. A method for preparing a homoallyl compound according to claim 1 or 2, characterized in that: The preparation method comprises the following steps: In the presence of an acid catalyst, the compound represented by formula II and the compound represented by formula III are mixed and reacted to obtain the compound represented by formula IV. The reaction formula is as follows: The acid catalyst is Alternatively, the preparation method further comprises the following steps: The compound represented by formula IV is subjected to an oxidation reaction to obtain a compound represented by formula V. The reaction formula is as follows:
7. The preparation method according to claim 6, characterized in that: The molar ratio of the compound represented by formula II to the compound represented by formula III is 1:(0.8-1.2).
8. The preparation method according to claim 6, characterized in that: The molar ratio of the compound represented by formula II to the acid catalyst is 1:(0.05-0.3).
9. The preparation method according to claim 6, characterized in that: The temperature for the mixed reaction of the compound represented by formula II and the compound represented by formula III is -94-30°C and the time is 4-24h.
10. The preparation method according to claim 6, characterized in that: The mixed reaction of the compound represented by formula II and the compound represented by formula III is carried out in a solvent, and the solvent includes toluene.
11. The preparation method according to claim 6, characterized in that: The compound represented by formula IV undergoes an oxidation reaction in the presence of an oxidant, wherein the oxidant comprises (NH4)6Mo7O 24 (H2O)4.
12. The preparation method according to claim 6, characterized in that: The temperature for the oxidation reaction of the compound represented by formula IV is 25-35° C. and the time is 20-30 hours.
13. The preparation method according to claim 6, characterized in that: The compound represented by formula IV undergoes an oxidation reaction in the presence of a solvent, and the solvent includes ethanol.
14. Use of a homoallyl compound according to claim 1 or 2, or an enantiomer, diastereomer or a pharmaceutically acceptable salt thereof of a homoallyl compound according to any one of claims 3 to 5 in the preparation of a coronavirus 3CL protease inhibitor.
